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from	 two	platforms	 (Illumina	MiSeq,	 Ion	 Torrent	 PGM™)	 and	 two	 rapid	 analytic	 pipelines	
(TBProfiler,	Mykrobe	predictor).	DNA	 replicates	 from	 the	 reference	 strain	 (H37Rv)	 and	10	









M.	 aurum	 is	 an	 environmental	mycobacteria	 that	 has	 been	 proposed	 as	 a	model	 for	 the	































































































































































































































































































difficult	 due	 to	 increasing	drug	 resistance	 and	 in	 some	populations	HIV	 co-infection1.	 The	
majority	of	new	cases	(60%)	were	from	China,	India,	Indonesia,	Nigeria,	Pakistan	and	South	
Africa1	(Figure	1).	HIV	infection	increases	the	incidence	and	mortality	risk	of	the	disease,	and	
1.2	million	 (11%)	of	new	cases	were	HIV-positive1.	One	of	 the	aims	set	out	by	 the	End	TB	









containing	 the	 bacterium	 are	 inhaled,	 reach	 the	 alveoli	 and	 invoke	 an	 immune	 response	
though	 macrophages	 and	 granulocytes.	 Once	 the	 bacilli	 have	 entered	 the	 lung	 they	 are	
engulfed	by	macrophages	which	move	 into	 deeper	 tissue.	Mtb	 then	 replicates	within	 the	
macrophage	–	eventually	causing	apoptosis	and	rupture	of	the	host	cell.	More	macrophages	
are	recruited	to	engulf	the	debris	and	the	granuloma	is	formed	through	the	recruitment	of	










that	 susceptibility	may	 be	 heritable,	with	 higher	 concordance	 for	 the	 development	 of	 TB	
among	mono-	as	opposed	to	di-zygotic	twins5.	Using	experimental	and	molecular	approaches,	
some	 genetic	 differences	 between	 populations	 contributing	 towards	 the	 altered	 level	 of	












studies,	while	useful	 in	demonstrating	that	host	genetics	 is	a	 factor	 in	susceptibility	to	TB,	
analysed	rare	variants	which	would	not	be	expected	to	exist	at	high	frequencies	 in	human	
populations.	 Identification	 of	 other	 host	 genetic	 variants	 affecting	 susceptibility	 is	 vital,	
especially	 to	 improve	patient	management,	and	genome	wide	association	 studies	 (GWAS)	






Russian	population	 and	 	 identified	 7	 SNPs	on	 chromosome	8	 in	 the	ASAP1	 gene	 as	 being	
associated	 with	 susceptibility	 to	 TB	 9.	 However	 a	 subsequent	 study	 in	 a	 Chinese	 Han	














chest	 x-ray	 and	 used	 to	 diagnose	 TB.	 However,	 symptoms	 can	 overlap	 with	 other	 more	
common	 diseases	 in	 low	 endemic	 countries	 and	 do	 not	 immediately	 point	 towards	 TB.	
Additionally,	interpretation	of	x-rays	requires	experience	and	is	subjective.	Smear	microscopy	




Xpert	 MTB/RIF	 assay	 can	 detect	Mtb	 with	 an	 increased	 sensitivity	 and	 can	 also	 detect	
resistance	 to	 certain	drugs,	 in	 this	 case	 rifampicin15.	 Recent	 efforts	 have	 concentrated	on	
detecting	Mtb	nucleic	acids	by	sequencing	direct	from	sputum19	or	with	limited	culturing20.	




are	 subdivided	 into	 two	main	 categories.	 The	 first	 line	drugs	 include	 rifampicin,	 isoniazid,	
ethambutol,	streptomycin	and	pyrazinamide.	Second	line	drugs	such	as	fluoroquinolones	and	
injectables	should	be	supplemented	when	treatment	 fails	with	the	above	(Table	1).	Other	


















































region	 in	 rpoB	 called	 the	 rifampicin	 resistance-determining	 region	 (RRDR)35.	 Isoniazid	 is	 a	
prodrug	which	is	activated	by	KatG	catalase-peroxidase	and	binds	to	InhA	to	inhibit	mycolic	
acid	synthesis36.	Mutations	in	the	katG	gene	or	in	the	inhA	promoter	lead	to	resistance37,38.	















































and	 it	 should	 be	 using	 in	 conjunction	with	 a	 high-resolution	method.	 Another	 PCR	 based	
approach	that	has	gained	popularity	is	the	MIRU-VNTR	method46.	This	involved	the	analysis	
of	 variable	 number	 of	 tandem	 repeats	 (VNTR)	 of	 24	 repetitive	 loci	 in	 the	Mtb	 genome	
including	the	mycobacterial	interspersed	repetitive	units	(MIRU)47.	The	loci	are	amplified	and	
the	number	of	repeats	at	each	locus	is	estimated	leading	to	a	unique	barcode	which	can	be	
translated	 to	 a	 strain	 type.	 Using	 these	 methods	 many	 different	 strain	 types	 have	 been	
defined	and	deposited	into	databases	such	as	SITVIT48	and	SpolDB449.		
These	genotyping	methods	use	 less	 than	1%	of	 the	Mtb	genome	(size:	4.4Mbp).	 In	
silico	 methods	 have	 also	 been	 developed	 to	 profile	 spoligotypes	 from	 whole	 genome	
sequence	data50.	Using	these	typing	methods	 in	conjunction	with	analysing	 long	sequence	




(lineage	7)	according	 to	where	 in	 the	 tree	 they	diverged	 from	 the	ancestral	outgroup	 (M.	
canetti).	 Studies	 on	 the	 phylogeographic	 spread	 of	Mtb	 have	 shown	 a	 strong	 correlation	
between	the	strain	type	and	geographic	location51.	This	observation	has	led	to	the	hypothesis	
that	Mtb	 travelled	 with	 and	 co-evolved	 with	 their	 human	 hosts	 during	 the	 out	 of	 Africa	
expansion52	 .	 The	 lineages	 are	 postulated	 to	 have	 differential	 impacts	 on	 pathogenesis,	
 21 
disease	 outcome	 and	 vaccine	 efficacy53–56.	 For	 example,	modern	 lineages,	 such	 as	 Beijing	
(lineage	2)	and	Euro-American	Haarlem	(lineage	4)	strains	exhibit	more	virulent	phenotypes	
compared	 to	 ancient	 lineages,	 such	 as	 Indo-Oceanic57.	 Whilst	 some	 genetic	 differences	
































in	 lieu	 of	 experimental	 and	 functional	 work,	 insights	 into	 their	 function	 and	 interaction	
partners	must	come	from	 in	silico	analysis	of	 large-scale	 ‘omics	data.	However,	due	to	the	
repetitive	 nature	 and	 high	GC	 content	 genetic	 variation	 in	 the	pe/ppe	genes,	 it	 has	 been	








NGS	 platforms	 have	 been	 developed	 including	 Illumina,	 454	 and	 Ion	 Torrent71,72.	 These	
platforms	 use	 a	 different	 set	 of	 reactions/processes	 however	 they	 all	 rely	 on	 the	 same	
principle:	the	DNA/genome	is	cut	into	smaller	fragments	and	sequenced	in	parallel	to	produce	
a	 large	 number	 of	 overlapping	 sequences	 (reads).	 These	 sequences	 can	 be	 aligned	 to	 a	
reference	 genome	 or	 assembled	 de	 novo	 to	 build	 up	 a	 picture	 of	 the	 DNA	 which	 was	
sequenced.	 NGS	 has	 numerous	 advantages	 over	 sanger	 sequencing	 including	 cost,	
throughput	and	accuracy.	The	human	genome	project	cost	$3	billion	and	took	13	years	to	
complete.	 With	 NGS	 it	 is	 now	 possible	 to	 sequence	 a	 human	 genome	 in	 three	 days	 for	











of	 a	 repeat	 using	 sequence	 information	 alone.	 	 Advancing	 on	 short-read	 sequencing	
technologies,	so	called	third-generation	NGS	platforms	have	tried	to	circumvent	these	issues.	
These	 include	 Pacific	 Biosciences	 (PacBio)74	 and	 Oxford	 Nanopore	 minION75.	 Both	 these	
platforms	have	the	ability	to	sequence	much	longer	fragments,	leading	to	the	production	of	
reads	greater	than	10Kb.	The	reads	are	 long	enough	to	span	entire	repetitive	elements	of	
Mtb.	 PacBio	 technology	 relies	 on	 sequencing	 of	 a	 template	 strand	 by	 a	 modified	 DNA	
polymerase.	This	process	produces	an	optical	signal	which	can	be	translated	into	a	nucleotide	
base.	Additionally,	PacBio	captures	the	speed	at	which	a	base	is	incorporated.	DNA	that	has	
been	methylated	will	 take	 longer	 to	 pass	 through	 the	polymerase.	 This	 differential	 speed	
allows	 for	 the	 epigenetic	 modifications	 to	 be	 detected.	 The	 minION	 uses	 a	 different	
technology,	 instead	 measuring	 the	 electrical	 current	 changes	 as	 a	 DNA	 molecule	 passes	




is	 still	 not	 cost	effective	 to	 run	on	a	 large	 scale	 for	human	 studies	 such	as	GWASs.	 These	
studies	 use	 single	 nucleotide	 polymorphism	 (SNP)	 arrays	 to	 identify	 genetic	 differences,	
 25 







detection	 of	 drug	 resistance	 and	 the	 large-scale	 study	 of	 transmission.	 NGS	 can	 detect	
differences	 between	 samples	 on	 a	 single	 base	 resolution.	 This	 fine-scale	 has	 made	 it	 an	
excellent	choice	of	 tool	 in	 the	 field	of	 strain	 typing.	Previous	 technologies	such	as	 IS6110,	
spoligotyping	and	MIRU-VNTR	typing	suffer	from	low	resolution	and	convergent	evolution	of	











cut-off	 for	 recent	 transmission83,84.	 	 	 NGS	 can	 also	 help	 to	 disentangle	 the	 origin	 of	 drug	
 26 
resistance	in	a	patient;	acquired	or	transmitted.	Acquired	drug	resistance	refers	to	the	micro	










database.	 Several	 computer	 programs	 providing	 fast	 and	 accurate	 prediction	 of	 drug	
resistance	 have	 been	 developed	 including	 TBProfiler,	Mykrobe-predictor,	 PhyResSE21,87,88.	
One	 limitation	with	 these	 tools	 is	 the	underlying	database.	As	 sequencing	becomes	more	
common,	new	drug	resistance	variants	will	be	detected	or	characterised,	which	have	not	been	
included	 in	 current	 databases.	 Recent	 consortial	 efforts	 are	 attempting	 to	 establish	 new	
databases	 based	 on	 whole	 genome	 sequence	 data	 and	 well	 characterised	 resistance	
phenotypes	(ReSeqTB)89.	Sequencing	projects	aiming	to	detect	novel	drug	resistant	variants	
are	of	great	importance	and	will	improve	the	diagnostic	sensitivity	of	these	tools.	NGS	can	be	
envisioned	 running	 along	 standard	 diagnostics,	 helping	 to	 perform	 rapid	 in-silico	 drug	
resistance	profiling	to	inform	drug	choices	and	identifying	transmission	events.	Examples	of	
its	 use	 in	 a	 clinical	 setting	 have	 already	 been	 demonstrated90,91	 and	 it	will	 become	more	




Raw	 sequence	data	 and	 its	 associated	quality	 from	next	 generation	 sequencing	machines	
typically	is	stored	in	text	files	called	fastq	files.	The	quality	for	each	base	is	stored	in	the	form	
of	a	phred	quality	score.	The	phred	quality	score	represents	the	probability	that	the	called	
base	 is	 incorrect.	 The	 raw	 sequence	 data	 can	 either	 be	 aligned	 to	 a	 reference	 genome	
(mapping)	or	assembled	de	novo.	Mapping	is	used	when	fast	accurate	characterisation	of	non-
repetitive	 regions	 is	 required.	A	multitude	of	 programs	 are	 available	 to	 perform	mapping	
including	 BWA	 and	 bowtie92,93.	 The	 mapping	 process	 consists	 of	 finding	 the	 optimum	







files	 (VCF).	 A	 filtering	 step	 is	 required	 to	 take	 only	 high	 quality	 variants	 to	 downstream	
analyses.	Variants	with	high	quality	score	(Q>23),	minimum	depth	of	10	and	greater	than	70%	
of	 reads	 supporting	 the	 variant	 are	 used	 in	 the	 final	 dataset.	 Variants	 for	 all	 isolates	 in	 a	
dataset	 can	 be	 collated	 together	 in	 a	 large	 matrix	 where	 the	 rows	 are	 variants	 and	 the	













and	 pathogen.	 These	 phenotypes	 are	 the	 result	 of	 a	 vast	 number	 of	 proteins,	 lipids	 and	
carbohydrates	interacting	together.	In	turn	these	proteins	are	coded	for	by	the	DNA	and	any	
variation	 in	 this	 sequence	 will	 have	 a	 knock-on	 effect	 on	 the	 phenotype.	 Though	 this	
representation	 is	 over	 simplified	 and	 disregards	 environmental	 and	 other	 stochastic	
processes,	 there	 is	 no	 doubt	 that	 variation	 in	 the	 genome	 influences	 the	 phenotype	
presented.	 For	 example,	 at	 an	 individual	 pathogen	 resolution	 there	 is	 evolution	 of	 drug	
resistance,	and	at	a	population	scale,	transmission	dynamics	of	a	strain	and	clonal	outbreaks.	
The	main	 theme	of	 this	work	 is	 to	 analyse	 variation	 in	 the	host	 and	pathogen	 to	provide	
insights	 into	 phenotypes.	 Whilst	 this	 is	 mainly	 genomic	 variation	 with	 regards	 to	 drug	
resistance,	 it	 gets	more	 complicated	when	analysing	phenotypes	 such	as	 clinical	outcome	
when	contact	with	the	host	is	involved.	The	variability	of	the	host	could	affect	the	variation	
of	 the	 bacterium	 and	 vice	 versa.	 The	 bacterium	 must	 be	 able	 to	 resist	 a	 wide	 range	 of	
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Gene	 Primer	 Primer	sequence		(5’-3’)	 Annealing	(0C)	
Length	
(bp)	 Ref.	










P5_Fw	 CGA	CAA	CGC	CAG	CTT	GGA	C	 518	P5_Rv	 CGG	TTC	CGG	TGC	CAT	ACG	
P6_Fw	 AGC	TCG	TAT	GGC	ACC	GGA	AC	 619	P6_Rv	 TGA	CCT	CCC	ACC	CGA	CTT	GT	
P7_Fw	 ACA	AGT	CGG	GTG	GGA	GGT	C	 574	P7_Rv	 CTG	CCG	GTC	CAC	TTC	ACC	TT	
P8_Fw	 GGG	ACC	TAC	CAG	GGC	AAG	GA	 629	P8_Rv	 CCG	GGA	GTC	AGC	AAG	TCA	CC	
tlyA	 tlyAs	 GCA	TCG	CAC	GTC	GTC	TTT	 55	 947	 D	tlyAas	 GGT	CTC	GGT	GGC	TTC	GTC	
eis	 eisF1		 GCC	ATG	GGA	CCG	GTA	CTT	GC		 56	 601	 E	eisR1		 GTA	GAT	GCC	GCC	CTC	GCT	AG	





pncA_promP1	 GCT	GGT	CAT	GTT	CGC	GAT	CG	 55	 214	 G	pncA_promP2	 TCG	GCC	AGG	TAG	TCG	CTG	AT	
pncA_Fw	 AGT	CGC	CCG	AAC	GTA	TGG	TG	 62	 615	 H	pncA_Rv	 CAA	CAG	TTC	ATC	CCG	GTT	CG	
gyrA	 gyrA_Fw	 ATC	GCC	GGG	TGC	TCT	ATG	 62	 321	 F	gyrA_Rv	 GGC	CGT	CGT	AGT	TAG	GGA	TG	
ethA	
ethA1	 ATC	ATC	GTC	GTC	TGA	CTA	TGG	 55	 667	
A	
ethA5	 ACT	ACA	ACC	CCT	GGG	ACC	
ethA4	 CCT	CGA	CCT	TCC	CGT	GA	 64	 692	ethA9	 CCT	CGA	GTA	CGT	CAA	GAG	CAC	
ethA8	 GGT	GGA	ACC	GGA	TAT	GCC	TG	 68	 342	ethA10	 CGT	TGA	CGG	CCT	CGA	CAT	TAC	
embB	 embB-F2	 AAC	CTG	CGC	CCG	CAG	ATT	GTC	 62	 526	 I	embB-R2	 GGT	CTG	GCA	GGC	GCA	TCC	
	 embBR2_Fw	 CTG	GCG	CTG	ATG	ACC	CAT	 62		 588	 *		 embBR2_Rv		 GGT	GGG	CAG	GAT	GAG	GTA	G	 	 	
embC-
embA	IRG	
embC-embA_Fw	 GGT	TGA	CGC	CTT	ACT	ACC	C	 62	 535	 J	
	 embC-embA_Rv	 CCA	CGA	CGA	CCG	TGT	CC	 	 	
rpsL	 rpsL_Fw	 GGC	CGA	CAA	ACA	GAA	CGT	 64	 504	 K	
rpsL_Rv	 GTT	CAC	CAA	CTG	GGT	GAC	
folC	 folCP1-Fw	 CGC	TGC	AAT	GAA	TTC	GAC	GA	 62	 668	 *	
	 folCP1-Rv	 TGA	TGA	TGC	CCG	CCT	TCT	C	 	 	
thyX	 thyXprom_Fw	 TGG	ATG	GAA	AAC	CTT	GCG	G	 62	 558	 *	
	 thyXprom_Rv		 TCG	GTC	TTG	GCG	ATC	AGT	T	 	 	
	 thyX-F2		 CTA	CTC	GCA	GCT	CTC	CCA	G	 62	 510	 *	











High-level	 resistance	 to	 isoniazid	 and	 ethionamide	 in	 multidrug-resistant	




Sequence	 analyses	 of	 just	 four	 genes	 to	 detect	 extensively	 drug-resistant	



























[K]	 Sreevatsan	 S,	 Pan	 X,	 Stockbauer	 K,	 Williams	 D,	 Kreiswirth	 B,	 Musser	 J.	



















MiSeq	 POR1A	 874721	 222	 0.95	 40	 766	
MiSeq	 POR1B	 1280618	 221	 0.96	 55	 766	
MiSeq	 POR1C	 1068336	 221	 0.96	 48	 766	
Ion	PGM	 POR1A	 1015193	 335	 0.73	 48	 512	
Ion	PGM	 POR1B	 1124215	 339	 0.67	 52	 512	
MiSeq	 POR2A	 1167341	 224	 0.97	 53	 854	
MiSeq	 POR2B	 871084	 223	 0.97	 38	 854	
MiSeq	 POR2C	 817606	 224	 0.97	 36	 854	
Ion	PGM	 POR2A	 929733	 213	 0.73	 28	 594	
Ion	PGM	 POR2C	 966514	 326	 0.74	 46	 594	
MiSeq	 POR3A	 1217694	 224	 0.96	 55	 771	
MiSeq	 POR3B	 1100251	 222	 0.96	 50	 771	
MiSeq	 POR3C	 413660	 215	 0.93	 18	 773	
MiSeq	 POR4A	 1055194	 218	 0.96	 47	 795	
MiSeq	 POR4B	 1100448	 224	 0.96	 50	 795	
MiSeq	 POR4C	 1071269	 225	 0.96	 49	 795	
MiSeq	 POR5A*	 988848	 224	 0.96	 45	 758	
MiSeq	 POR5B	 1111052	 224	 0.96	 51	 758	
MiSeq	 POR5C	 1113854	 223	 0.96	 50	 758	
MiSeq	 POR6A*	 2269310	 180	 0.97	 70	 767	
MiSeq	 POR6B	 1201932	 222	 0.96	 53	 767	
MiSeq	 POR6C	 774063	 222	 0.96	 34	 767	
Ion	PGM	 POR6B	 1049314	 338	 0.72	 44	 510	
Ion	PGM	 POR6C	 904304	 325	 0.73	 42	 510	
MiSeq	 POR7A*	 2423026	 179	 0.97	 70	 801	
MiSeq	 POR7B	 1129806	 222	 0.96	 51	 801	
MiSeq	 POR7C	 2638858	 155	 0.97	 65	 801	
MiSeq	 POR8A	 2851160	 172	 0.97	 79	 770	
MiSeq	 POR8B	 1028634	 225	 0.96	 49	 770	
MiSeq	 POR8C	 801687	 222	 0.96	 36	 770	
MiSeq	 POR9A	 2091394	 180	 0.97	 61	 796	
MiSeq	 POR9B	 1145983	 225	 0.96	 53	 796	
MiSeq	 POR9C	 1128251	 223	 0.96	 51	 796	
MiSeq	 POR10A	 1074170	 217	 0.97	 48	 902	
MiSeq	 POR10B	 1224053	 223	 0.97	 54	 902	
MiSeq	 POR10C	 894289	 223	 0.97	 39	 902	
MiSeq	 H37Rv*	 2652971	 156	 0.99	 56	 62	


















































	 Technical	 	 	 	 	 	 	 	 	
MiSeq	 POR5A	




MiSeq	 POR6A		(6,X)	 846	 815	 92.2	
87/103	(0.84)	 65/127	(0.51)	
81.1	
XDR-TB	 ETB,	 PZA,	 STR,	 FLQ,	
AMK,	CAP,	KAN	
MiSeq	 POR7A	(6,X)	 858	 839	 97.1	
90/102	(0.88)	 72/133	(0.54)	
76.7	
XDR-TB	 ETB,	 PZA,	 STR,	 FLQ,	
AMK,	CAP,	KAN	
MiSeq	 H37Rv	(6,S)	 81	 70	 84.1	 22/27	(0.81)	 16/40	(0.40)	 67.5	 Susc.	 	











XDR-TB	 ETB,	 PZA,	 STR,	 FLQ,	
AMK,	CAP,	KAN	
MiSeq	 POR2	(3,M)	 875	 846	 96.7	 99/114	(0.87)	 88/115	(0.77)	 99.1	 MDR-TB	 	











XDR-TB	 ETB,	 PZA,	 STR,	 FLQ,	
AMK,	KAN	






























XDR-TB	 ETB,	 PZA,	 STR,	 FLQ,	
AMK,	CAP,	KAN	
MiSeq	 POR10	
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	 	 Number	of	isolates	belonging	to	lineage	 Number	of	isolates	showing	resistance	to	
Source	 Tot.	 L1	 L2	 L3	 L4	 SM	 INH	 RMP	 EMB	 OFL	 KAN	 CAP	 Et	 PZA	
Asia	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Bangladesh	 8	 4	 1	 1	 2	 2	 4	 1	 4	 1	 -	 -	 1	 -	
China	
(Tibet)	 1	 1	 -	 -	 -	 1	 1	 1	 -	 -	 -	 -	 -	 -	
Nepal	 4	 1	 2	 -	 1	 4	 3	 2	 1	 1	 -	 -	 -	 2	
Pakistan	 1	 -	 -	 1	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	
Philippines	 4	 4	 -	 -	 -	 1	 2	 2	 1	 -	 -	 -	 2	 -	
Sth	Korea	 39	 -	 23	 1	 15	 17	 26	 17	 15	 -	 -	 1	 1	 3	
Thailand	 1	 -	 1	 -	 -	 -	 -	 -	 -	 1	 1	 1	 -	 -	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Africa	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Cameroon	 1	 -	 -	 -	 1	 1	 -	 -	 -	 -	 -	 -	 -	 -	
CAR	 1	 -	 -	 -	 1	 -	 -	 -	 -	 1	 -	 -	 -	 -	
Guinea	 1	 -	 -	 -	 1	 -	 1	 -	 -	 -	 -	 -	 -	 -	
Guinea	Eq.	 1	 -	 -	 -	 1	 -	 1	 1	 -	 -	 -	 -	 1	 -	
Morocco	 4	 -	 -	 -	 4	 2	 3	 1	 1	 -	 -	 -	 -	 -	
Niger	 1	 -	 -	 -	 1	 -	 -	 -	 -	 -	 1	 1	 -	 -	
Nigeria	 2	 -	 -	 -	 2	 -	 1	 1	 -	 1	 -	 -	 1	 -	
RDC	 4	 -	 -	 -	 4	 -	 -	 -	 -	 -	 1	 1	 -	 -	
Rwanda	 15	 -	 -	 -	 15	 4	 15	 15	 10	 -	 -	 -	 1	 -	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
 93 
Europe	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Germany	 12	 -	 1	 1	 10	 3	 1	 1	 1	 1	 1	 1	 -	 -	
Kazakhstan	 1	 -	 -	 -	 1	 -	 -	 1	 -	 -	 -	 -	 -	 -	
Portugal	 1	 -	 -	 -	 1	 1	 1	 1	 -	 -	 -	 -	 -	 -	
Spain	 2	 -	 -	 -	 2	 1	 -	 1	 -	 -	 -	 -	 -	 -	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
South	America	 	 	 	 	 	 	 	 	 	 	 	 	 	
Brazil	 7	 -	 -	 -	 7	 2	 4	 4	 2	 1	 -	 -	 1	 1	
Colombia	 1	 -	 -	 -	 1	 -	 1	 1	 -	 -	 -	 -	 -	 -	
Peru	 31	 -	 5	 -	 26	 9	 9	 11	 6	 1	 -	 1	 1	 -	
Rep.	
Domin.	 1	 -	 -	 -	 1	 -	 -	 -	 -	 -	 -	 -	 -	 -	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	










ENA	Accession	 TDR	Accession	 RMP	MIC	 INH	MIC	 SM	MIC	 EMB	MIC	
ERR1213824	 TB-TDR-0070	 >120	 3.2	 4	 8	
ERR1213825	 TB-TDR-0073	 >120	 0.8	 ≤1	 4	
ERR1213826	 TB-TDR-0074	 80	 3.2	 2	 ≤1	
ERR1213827	 TB-TDR-0077	 30	 0.2	 2	 ≤1	
ERR1213828	 TB-TDR-0078	 ≤10	 0.2	 ≤1	 2	
ERR1213829	 TB-TDR-0079	 80	 0.2	 4	 ≤1	
ERR1213830	 TB-TDR-0080	 ≤10	 0.2	 ≤1	 ≤1	
ERR1213831	 TB-TDR-0081	 ≤10	 0.2	 ≤1	 2	
ERR1213832	 TB-TDR-0082	 ≤10	 3.2	 ≤1	 2	
ERR1213833	 TB-TDR-0083	 ≤10	 3.2	 ≤1	 ≤1	
ERR1213834	 TB-TDR-0084	 ≤10	 3.2	 ≤1	 ≤1	
ERR1213835	 TB-TDR-0085	 ≤10	 3.2	 8	 4	
ERR1213836	 TB-TDR-0086	 >120	 0.8	 ≤1	 2	
ERR1213837	 TB-TDR-0087	 >120	 3.2	 8	 4	
ERR1213838	 TB-TDR-0088	 >120	 0.2	 ≤1	 ≤1	
ERR1213839	 TB-TDR-0089	 >120	 0.8	 ≤1	 8	
ERR1213840	 TB-TDR-0090	 >120	 0.2	 ≤1	 2	
ERR1213841	 TB-TDR-0091	 20	 0.2	 2	 2	
ERR1213842	 TB-TDR-0092	 ≤10	 0.2	 2	 4	
ERR1213843	 TB-TDR-0093	 ≤10	 >3.2	 8	 4	
ERR1213844	 TB-TDR-0094	 ≤10	 0.2	 ≤1	 8	
ERR1213845	 TB-TDR-0095	 ≤10	 0.8	 >16	 ≤1	
ERR1213846	 TB-TDR-0096	 ≤10	 ≤0.05	 >16	 ≤1	
ERR1213847	 TB-TDR-0097	 30	 0.2	 >16	 ≤1	
ERR1213848	 TB-TDR-0098	 40	 0.2	 16	 2	
ERR1213849	 TB-TDR-0099	 >120	 >3.2	 4	 >8	
ERR1213850	 TB-TDR-0101	 80	 3.2	 2	 4	
ERR1213851	 TB-TDR-0102	 >120	 3.2	 ≤1	 2	
ERR1213852	 TB-TDR-0104	 ≤10	 >3.2	 ≤1	 4	
ERR1213853	 TB-TDR-0106	 >120	 3.2	 ≤1	 2	
ERR1213854	 TB-TDR-0108	 ≤10	 0.8	 8	 ≤1	
ERR1213855	 TB-TDR-0109	 ≤10	 3.2	 >16	 2	
ERR1213856	 TB-TDR-0110	 ≤10	 >3.2	 >16	 2	
ERR1213857	 TB-TDR-0112	 >120	 0.8	 >16	 ≤1	
ERR1213858	 TB-TDR-0113	 120	 >3.2	 >16	 4	
ERR1213859	 TB-TDR-0116	 80	 >3.2	 8	 >8	
ERR1213860	 TB-TDR-0117	 >120	 >3.2	 ≤1	 2	
ERR1213861	 TB-TDR-0119	 >120	 3.2	 4	 ≤1	
ERR1213862	 TB-TDR-0120	 30	 >3.2	 16	 4	
ERR1213863	 TB-TDR-0122	 >120	 3.2	 >16	 4	
ERR1213864	 TB-TDR-0123	 20	 >3.2	 >16	 8	
ERR1213865	 TB-TDR-0124	 >120	 >3.2	 >16	 4	
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ERR1213866	 TB-TDR-0125	 >120	 0.2	 ≤1	 2	
ERR1213867	 TB-TDR-0126	 ≤10	 0.2	 2	 ≤1	
ERR1213868	 TB-TDR-0129	 >120	 1.6	 2	 ≤1	
ERR1213869	 TB-TDR-0130	 ≤10	 ≤0.05	 2	 ≤1	
ERR1213870	 TB-TDR-0131	 >120	 >3.2	 >16	 ≤1	
ERR1213871	 TB-TDR-0132	 ≤10	 >3.2	 4	 4	
ERR1213872	 TB-TDR-0133	 >120	 1.6	 8	 4	
ERR1213873	 TB-TDR-0134	 >120	 >3.2	 4	 ≤1	
ERR1213874	 TB-TDR-0135	 >120	 >3.2	 ≤1	 >8	
ERR1213875	 TB-TDR-0136	 ≤10	 ≤0.05	 2	 ≤1	
ERR1213876	 TB-TDR-0137	 ≤10	 ≤0.05	 2	 ≤1	
ERR1213877	 TB-TDR-0138	 ≤10	 ≤0.05	 2	 2	
ERR1213878	 TB-TDR-0139	 ≤10	 0.2	 2	 2	
ERR1213879	 TB-TDR-0140	 ≤10	 0.2	 ≤1	 ≤1	
ERR1213880	 TB-TDR-0141	 >120	 0.2	 >16	 ≤1	
ERR1213881	 TB-TDR-0142	 20	 0.2	 2	 2	
ERR1213882	 TB-TDR-0143	 ≤10	 0.2	 16	 2	
ERR1213883	 TB-TDR-0144	 ≤10	 >3.2	 >16	 4	
ERR1213884	 TB-TDR-0146	 40	 0.2	 8	 ≤1	
ERR1213885	 TB-TDR-0147	 20	 >3.2	 >16	 ≤1	
ERR1213886	 TB-TDR-0148	 >120	 >3.2	 >16	 2	
ERR1213887	 TB-TDR-0149	 >120	 >3.2	 >16	 4	
ERR1213888	 TB-TDR-0150	 >120	 1.6	 2	 ≤1	
ERR1213889	 TB-TDR-0152	 120	 3.2	 8	 8	
ERR1213890	 TB-TDR-0153	 80	 3.2	 4	 2	
ERR1213891	 TB-TDR-0155	 120	 >3.2	 2	 2	
ERR1213892	 TB-TDR-0156	 ≤10	 0.2	 2	 4	
ERR1213893	 TB-TDR-0157	 >120	 0.2	 >16	 2	
ERR1213894	 TB-TDR-0158	 ≤10	 ≤0.05	 2	 ≤1	
ERR1213895	 TB-TDR-0159	 ≤10	 ≤0.05	 2	 ≤1	
ERR1213896	 TB-TDR-0160	 80	 0.2	 8	 ≤1	
ERR1213897	 TB-TDR-0161	 ≤10	 ≤0.05	 ≤1	 ≤1	
ERR1213898	 TB-TDR-0163	 ≤10	 ≤0.05	 ≤1	 ≤1	
ERR1213899	 TB-TDR-0164	 ≤10	 ≤0.05	 8	 ≤1	
ERR1213900	 TB-TDR-0165	 >120	 0.2	 2	 ≤1	
ERR1213901	 TB-TDR-0166	 >120	 3.2	 >16	 2	
ERR1213902	 TB-TDR-0167	 >120	 3.2	 16	 4	
ERR1213903	 TB-TDR-0169	 ≤10	 ≤0.05	 >16	 ≤1	
ERR1213904	 TB-TDR-0170	 >120	 >3.2	 2	 4	
ERR1213905	 TB-TDR-0171	 >120	 0.2	 ≤1	 ≤1	
ERR1213906	 TB-TDR-0172	 20	 >3.2	 2	 ≤1	
ERR1213907	 TB-TDR-0173	 ≤10	 ≤0.05	 ≤1	 ≤1	
ERR1213908	 TB-TDR-0174	 ≤10	 ≤0.05	 2	 ≤1	
ERR1213909	 TB-TDR-0175	 >120	 0.8	 ≤1	 4	
ERR1213910	 TB-TDR-0176	 >120	 1.6	 >16	 2	
ERR1213911	 TB-TDR-0177	 20	 0.2	 2	 ≤1	
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ERR1213912	 TB-TDR-0178	 ≤10	 0.8	 2	 ≤1	
ERR1213913	 TB-TDR-0180	 ≤10	 0.2	 2	 ≤1	
ERR1213914	 TB-TDR-0181	 ≤10	 ≤0.05	 8	 2	
ERR1213915	 TB-TDR-0182	 20	 ≤0.05	 >16	 ≤1	
ERR1213916	 TB-TDR-0183	 >120	 0.8	 2	 ≤1	
ERR1213917	 TB-TDR-0184	 ≤10	 ≤0.05	 2	 ≤1	
ERR1213918	 TB-TDR-0185	 >120	 0.8	 2	 ≤1	
ERR1213919	 TB-TDR-0186	 >120	 >3.2	 ≤1	 ≤1	
ERR1213920	 TB-TDR-0187	 ≤10	 >3.2	 8	 2	
ERR1213921	 TB-TDR-0189	 >120	 >3.2	 8	 ≤1	
ERR1213922	 TB-TDR-0190	 >120	 ≤0.05	 >16	 ≤1	
ERR1213923	 TB-TDR-0191	 >120	 >3.2	 8	 8	
ERR1213924	 TB-TDR-0193	 >120	 >3.2	 >16	 2	
ERR1213925	 TB-TDR-0194	 20	 0.2	 2	 ≤1	
ERR1213926	 TB-TDR-0195	 20	 3.2	 2	 8	
ERR1213927	 TB-TDR-0197	 20	 0.2	 ≤1	 2	
ERR1213928	 TB-TDR-0198	 >120	 3.2	 8	 4	
ERR1213929	 TB-TDR-0199	 ≤10	 0.2	 ≤1	 2	
ERR1213930	 TB-TDR-0200	 ≤10	 ≤0.05	 ≤1	 ≤1	
ERR1213931	 TB-TDR-0201	 >120	 >3.2	 16	 ≤1	
ERR1213932	 TB-TDR-0202	 20	 ≤0.05	 4	 2	
ERR1213933	 TB-TDR-0203	 ≤10	 ≤0.05	 2	 ≤1	
ERR1213934	 TB-TDR-0204	 20	 ≤0.05	 4	 ≤1	
ERR1213935	 TB-TDR-0207	 ≤10	 ≤0.05	 2	 ≤1	
ERR1213936	 TB-TDR-0208	 20	 0.2	 ≤1	 ≤1	
ERR1213937	 TB-TDR-0209	 20	 0.2	 2	 ≤1	
ERR1213938	 TB-TDR-0210	 20	 ≤0.05	 ≤1	 ≤1	
ERR1213939	 TB-TDR-0213	 20	 0.8	 2	 ≤1	
ERR1213940	 TB-TDR-0214	 ≤10	 ≤0.05	 2	 ≤1	
ERR1213941	 TB-TDR-0016	 ≤10	 0.2	 ≤1	 2	
ERR1213942	 TB-TDR-0017	 ≤10	 0.2	 2	 ≤1	
ERR1213943	 TB-TDR-0018	 >120	 0.2	 ≤1	 ≤1	
ERR1213944	 TB-TDR-0022	 20	 ≤0.05	 2	 ≤1	
ERR1213945	 TB-TDR-0038	 ≤10	 >3.2	 >16	 ≤1	
ERR1213946	 TB-TDR-0041	 ≤10	 ≤0.05	 2	 ≤1	
ERR1213947	 TB-TDR-0042	 ≤10	 >3.2	 ≤1	 >8	
ERR1213948	 TB-TDR-0043	 20	 3.2	 ≤1	 8	
ERR1213949	 TB-TDR-0045	 ≤10	 0.2	 2	 4	












No.	samples	 Rifampicin	 Isoniazid	 Streptomycin	 Ethambutol	
12	(9.4%)	 R	 R	 R	 R	
8	(6.3%)	 R	 R	 R	 S	
8	(6.3%)	 R	 R	 S	 R	
14	(11.0%)	 R	 R	 S	 S	
4	(3.1%)	 R	 S	 R	 S	
7	(5.5%)	 R	 S	 S	 S	
5	(3.4%)	 S	 R	 R	 R	
7	(5.5%)	 S	 R	 R	 S	
5	(3.4%)	 S	 R	 S	 R	
6	(4.7%)	 S	 R	 S	 S	
9	(7.1%)	 S	 S	 R	 S	
4	(3.1%)	 S	 S	 S	 R	



































2	 rare	 	 	 Mean	 Min	 Max	
	 	 	 	 	 	 	 	 	 	 	 70	 15.3	 10.0	 80.0	
	 	 	 	 	 	 	 	 	 *	 	 5	 68.0	 10.0	 120.0	
	 	 	 	 	 	 	 	 *	 	 	 1	 10.0	 10.0	 10.0	
	 	 	 	 	 	 	 *	 	 	 	 1	 80.0	 80.0	 80.0	
	 	 	 	 	 	 *	 	 	 	 	 21	 114.3	 80.0	 120.0	
	 	 	 	 	 	 *	 	 	 	 *	 1	 120.0	 120.0	 120.0	
	 	 	 	 	 	 *	 	 	 *	 	 2	 120.0	 120.0	 120.0	
	 	 	 	 	 	 *	 	 	 *	 *	 1	 120.0	 120.0	 120.0	
	 	 	 	 	 	 *	 *	 	 	 	 1	 120.0	 120.0	 120.0	
	 	 	 	 	 	 **	 	 	 	 	 1	 120.0	 120.0	 120.0	
	 	 	 	 	 *	 	 	 	 	 	 9	 120.0	 120.0	 120.0	
	 	 	 	 *	 	 	 	 	 	 	 4	 120.0	 120.0	 120.0	
	 	 	 	 *	 	 	 	 *	 	 	 1	 120.0	 120.0	 120.0	
	 	 	 *	 	 	 *	 	 	 	 	 2	 120.0	 120.0	 120.0	
	 	 *	 	 	 	 	 	 	 	 	 2	 10.0	 10.0	 10.0	
	 *	 	 	 	 	 	 	 	 	 	 1	 120.0	 120.0	 120.0	
	 *	 	 	 	 	 	 	 	 *	 	 1	 120.0	 120.0	 120.0	







315	 436	 rare	 	 	 Mean	 Min	 Max	
	 	 	 	 46	 0.3	 0.05	 3.2	
	 	 *	 	 2	 0.2	 0.2	 0.2	
	 	 ***	 	 1	 3.2	 3.2	 3.2	
	 	 	 *	 8	 1.7	 0.8	 3.2	
	 	 *	 *	 1	 1.6	 1.6	 1.6	
*	 	 	 	 23	 2.9	 0.2	 3.2	
*	 	 *	 	 1	 3.2	 3.2	 3.2	
*	 	 	 *	 2	 3.2	 3.2	 3.2	
	 *	 	 	 18	 0.2	 0.05	 0.8	
	 *	 	 *	 4	 1.0	 0.8	 1.6	
	 *	 *	 *	 1	 3.2	 3.2	 3.2	
*	 *	 	 	 18	 3.2	 3.2	 3.2	
*	 *	 *	 	 1	 3.2	 3.2	 3.2	
*	 *	 	 *	 1	 3.2	 3.2	 3.2	
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c)	Streptomycin	
rpsL	codons	 rrs	 N	 MIC	(µg/ml)	
43	 88	 	 	 Mean	 Min	 Max	
	 	 	 99	 3.8	 1	 16	
	 	 *	 13	 10.0.4	 1	 16	
	 *	 	 4	 16.0	 16	 16	
*	 	 	 11	 16.0	 16	 16	
	
d)	Ethambutol	





























e	 	 	 	 Mean	 Min	 Max	
	 	 	 	 	 	 	 	 	 	 	 70	 1.2	 1	 2	
	 	 	 	 	 	 	 	 	 	 **	 1	 4.0	 4	 4	
	 	 	 	 	 	 	 	 	 *	 	 2	 1.5	 1	 2	
	 	 	 	 	 	 	 	 	 **	 	 1	 1.0	 1	 1	
	 	 	 	 	 	 	 	 *	 	 	 3	 1.7	 1	 2	
	 	 	 	 	 	 	 	 **	 	 	 1	 2.0	 2	 2	
	 	 	 	 	 	 	 *	 	 	 	 1	 4.0	 4	 4	
	 	 	 	 	 	 *	 	 	 	 	 5	 4.8	 4	 8	
	 	 	 	 	 	 *	 	 	 *	 	 1	 4.0	 4	 4	
	 	 	 	 	 *	 	 	 	 	 	 6	 4.5	 1	 8	
	 	 	 	 	 *	 	 	 	 *	 	 4	 2.8	 1	 4	
	 	 	 	 	 *	 	 *	 	 	 	 1	 4.0	 4	 4	
	 	 	 	 	 *	 	 *	 *	 	 	 1	 4.0	 4	 4	
	 	 	 	 *	 	 	 	 	 **	 	 3	 1.0	 1	 1	
	 	 	 	 *	 	 *	 	 *	 **	 	 1	 2.0	 2	 2	
	 	 	 *	 	 	 	 	 	 	 *	 1	 4.0	 4	 4	
	 	 	 *	 *	 	 	 	 	 **	 	 1	 4.0	 4	 4	
	 	 	 *	 *	 	 	 	 *	 **	 	 1	 4.0	 4	 4	
	 	 *	 	 	 	 	 	 	 	 	 3	 4.7	 2	 8	
	 *	 	 	 	 	 	 	 	 	 	 11	 4.1	 1	 8	
	 *	 	 	 	 	 	 	 	 	 *	 1	 4.0	 4	 4	
	 *	 	 	 	 	 	 	 	 *	 	 1	 8.0	 8	 8	
	 *	 	 	 	 	 	 	 *	 	 	 1	 2.0	 2	 2	
	 *	 	 	 *	 	 	 	 	 **	 	 2	 8.0	 8	 8	
	 *	 	 *	 	 	 	 	 	 	 	 1	 8.0	 8	 8	
*	 	 	 	 	 	 	 	 	 	 	 2	 2.5	 1	 4	




















T400A	 	 42.914	 0.031	 -0.326	 2.480	
D435V	 	 3.094	 0.336	 0.356	 1.860	
H445D	 	 4.015	 -2.084	 -1.971	 -1.730	
H445Y	 	 4.015	 -0.214	 -0.171	 -0.310	
H445R	 	 4.015	 -1.958	 -1.857	 -1.950	
S450W	 	 5.773	 -0.756	 -0.840	 2.330	
S450L	 	 5.773	 0.102	 -0.126	 2.820	
I491V	 	 2.908	 -1.221	 -1.274	 -0.830	
I491F	 	 2.908	 -1.529	 -1.416	 -0.760	
katG	
	
S315N	 14.940	 2.149	 -0.100	 -0.184	 2.149	
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we	 performed	 a	 genome-wide	 association	 study	 (GWAS)	 of	 6,465	 Mycobacterium	
tuberculosis	clinical	isolates	from	more	than	30	countries.		A	GWAS	approach	within	a	
mixed	regression	framework	was	followed	by	a	phylogenetic-based	test	for	independent	
mutations.	 In	 addition	 to	 novel	mutations	 associated	with	 resistance	 to	 cycloserine,	
ethionamide	and	p-aminosalicylic	acid	our	analysis	indicates	a	more	extensive	role	for	
small	 insertions	 and	 deletions	 and	 large	 deletions	 than	 previously	 recognised,	
particularly	 for	 ethionamide,	 pyrazinamide,	 capreomycin,	 cycloserine	 and	 para-
aminosalicylic	 acid.	 Findings	 also	 suggest	 the	 involvement	 of	 efflux	 pumps	 (drrA,	
Rv2688c)	 in	 the	emergence	of	 resistance.	Odds	ratios	 for	mutations	 in	candidate	 loci	










anti-tuberculous	 drugs	 is	 of	 global	 concern.	 Programmatically	 incurable	 tuberculosis	
(TB),	where	effective	treatment	regimens	cannot	be	provided	due	to	resistance	to	the	
available	drugs	is	a	growing	problem1.	 In	high	burden	countries	such	patients	may	be	
discharged	 to	 home	 care,	 increasing	 the	 risk	 of	 community	 based	 transmission	 of	
incurable	drug	 resistant	disease2.	 Resistance	 to	 rifampicin	 and	 isoniazid	 is	 classed	 as	
multidrug-resistant	tuberculosis	 (MDR-TB),	 further	resistance	to	the	fluoroquinolones	
and	 any	of	 the	 injectable	 drugs	 (amikacin,	 kanamycin	or	 capreomycin)	 used	 to	 treat	
MDR-TB	 is	 termed	 extensively	 drug-resistant	 (XDR-TB).	 Strains	 resistant	 to	 the	
remaining	drugs,	are	referred	to	as	XXDR-TB	or	totally	drug-resistant	(TDR-TB),	however	
formal	definitions	for	post	XDR-TB	resistance	have	yet	to	be	agreed	by	the	World	Health	
Organisation	 (WHO)1.	 Treatment	 for	 patients	 with	 drug	 resistant	 tuberculosis	 is	
prolonged,	 expensive	 and	 outcomes	 are	 poor3.	 The	 drugs	 used	 are	 toxic	 and	 poorly	
tolerated,	adverse	events	are	common	and	may	be	severe	and	irreversible4.	Inadequate	
treatment	 also	 risks	 amplification	 of	 resistance	 to	 further	 drugs	 and	 may	 prolong	
opportunities	for	transmission5.		
	
Mtb	 has	a	 clonal	 genome	 (size	4.4Mb)	with	a	 low	mutation	 rate	and	no	evidence	of	
between-strain	recombination	or	horizontal	gene	transfer6.	The	Mtb	complex	comprises	
seven	lineages,	of	which	four	are	predominant	in	humans:	Lineage	1,	Indo-Oceanic	(e.g.	
East-African-Indian	 (EAI)	 spoligotype	 families);	 Lineage	 2,	 East-Asian	 (e.g.	 W/Beijing	
spoligotype	families);	Lineage	3,	East-African-Indian	(e.g.	Central-Asian-Strain	(e.g.	CAS-
DELHI)	 spoligotype	 families)	 and	 Lineage	 4,	 Euro-American	 (e.g.	 Latin	 American-
Mediterranean	(LAM),	Haarlem	and	the	“ill-defined”	T	spoligotype	families)6.	
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Resistance	 in	 Mtb	 is	 mainly	 conferred	 by	 nucleotide	 variations	 (single	 nucleotide	
polymorphisms,	insertions	and	deletions	(indels))	in	genes	coding	for	drug-targets	or	-
converting	 enzymes.	 Changes	 in	 efflux	 pump	 regulation	may	 have	 an	 impact	 on	 the	
emergence	of	resistance7	and	putative	compensatory	mechanisms	to	overcome	fitness	
impairment	 coincidental	 with	 the	 acquisition	 of	 resistance	 have	 been	 described	 for	
some	drugs8.	 	Detection	of	 resistance	conferring	mutations	offers	a	means	of	 rapidly	
identifying	resistance	to	anti-tuberculosis	drugs9	but,	with	the	exception	of	rifampicin,	
current	 molecular	 tests	 for	 resistance	 lack	 high	 levels	 of	 sensitivity9.	 To	 improve	





with	 available	 phenotypic	 data	 on	 drug	 susceptibility	 testing	 were	 investigated	
(Supplementary	table	2).	Phenotypic	drug	susceptibility	data	was	not	available	for	each	
of	the	14	drugs	for	every	isolate	and	sample	sizes	ranged	from	over	6,000	for	the	most	
commonly	 tested	 first	 line	 drugs	 (isoniazid	 and	 rifampicin)	 to	 255	 and	 248	 for	 p-
aminosalicylic	acid	and	cycloserine,	respectively,	which	are	used	to	treat	patients	with	
XDR-TB.	Here,	we	present	findings	from	the	most	comprehensive	study	yet	undertaken	








High	quality	 genome-wide	 SNPs	 (102,160),	 indels	 (11,122),	 and	 large	deletions	 (284)	











TB	 (Supplementary	 table	2,	Figure	2).	Fourteen	drugs	were	 included	 in	 the	genome-
wide	analysis:	isoniazid	(INH),	rifampicin	(RIF),	ethionamide	(ETH),	pyrazinamide	(PZA),	






with	 drug	 resistance	 complementary	 methods	 were	 applied	 to	 mutations	 and	
aggregated	 non-synonymous	 mutations,	 a	 tree-based	 “PhyC”	 test	 for	 convergent	
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evolution	 to	 detect	 homoplastic	 variants10	 and	 a	 GWAS	 approach	 within	 a	 mixed	
regression	framework	(See	Online	methods).	Specifically,	the	low	frequency	of	variants	





The	 phylogenetic-based	 “PhyC”	 test	 was	 applied	 to	 provide	 further	 evolutionary	
evidence.	We	report	all	findings	that	are	below	a	calculated	permutation	threshold	of	







The	 gene-based	GWAS	of	MDR-TB	 versus	 susceptible	 identified	 rpoB	 (RIF),	Rv1482c-
fabG1	operon	(INH,	ETH),	inhA	(INH,	ETH)	and	katG	(INH).	The	katG	mutations	at	codon	
315	 (S315T,	 S315N,	 S315R)	were	all	 statistically	 significant,	 and	collectively	were	 the	
most	frequent	mutations	(81.7%)	across	all	resistance	loci	identified,	consistent	with	a	
recent	study16	and	highlighting	their	pivotal	role	in	the	emergence	of	INH	resistance	and	
MDR-TB.	 The	 katG	 S315T	 mutation	 is	 thought	 to	 emerge	 before	 RIF	 resistance	
associated	 mutations	 and	 therefore,	 from	 an	 evolutionary	 standpoint,	 preclude	 the	
emergence	of	MDR-TB16,17.	However,	our	analysis	highlighted	that	Rv1482c-fabG1	and	
 119 
inhA	 mutations,	 in	 the	 absence	 of	 katG	 S315T,	 can	 emerge	 prior	 to	 MDR-TB,	 as	
previously	shown	in	two	phylogenetically-independent	clades	in	Lisbon18,19.	The	other	






(PAS),	pncA-Rv2044c	 intergenic	 region	 (PZA),	 and	whiB6-Rv3863	 intergenic	 (putative	
STM	or	ETH)	regions.		
	
The	gene-based	GWAS	of	XDR-TB	versus	MDR-TB	 identified	mutations	 in	gyrA	 (FLQ),	
rpoB	(RIF),	rrs	(aminoglycosides)	and	ubiA	(EMB).	One	ubiA	mutation	(T180V,	EMB)	has	
not	been	previously	reported	and	was	found	using	the	SNP-based	GWAS	approach.	The	
PhyC	 test	 additionally	 revealed	 eis-Rv2417c	 (KAN),	 gyrB	 (FLQ),	 rrs	 (aminoglycosides)	
SNPs,	and	a	novel	mutation	in	the	thyX-hsdS.1	intergenic	region	(A-9T,	PAS).20,21	
	
The	 gene-based	 GWAS	 comparing	 XDR-TB	 to	 susceptible	 identified	 rpoC	 (a	









on	 its	 strong	association	with	XDR-TB	 in	our	study	and	 its	 functional	annotation	as	a	
probable	 transporter	 of	 antibiotics	 across	 the	membrane	 (http://tuberculist.epfl.ch).	
This	 hypothesis	 is	 in	 accordance	 with	 the	 findings	 that	 rpoB	 mutations	 in	Mtb	 may	
trigger	 compensatory	 transcriptional	 changes	 in	 secondary	 metabolism	 genes,	 in	
particular,	 in	 the	 biosynthesis	 and	 export	 of	 phthiocerol	 dimycocerosate	 (PDIM),	




Similarly,	 a	mutation	 in	 the	Rv1144-mmpL13a	 intergenic	 region	 (C-102A)	was	 highly	
associated	 with	 XDR-TB	 versus	 susceptible	 (mutation	 frequency	 19%	 vs.	 0%,	






with	 drug	 resistance.	 The	 majority	 of	 associations	 were	 present	 in	 more	 than	 one	
lineage.	The	largest	number	of	lineage-specific	drug	resistance	mutations	were	found	in	
lineage	4,	which	was	the	largest	collection	investigated	and	contained	more	genetically	
diverse	clones6,	 implying	 that	geographically	 restricted	mutations	are	being	captured	
(Supplementary	 table	 4).	 A	 previously	 unreported	 putative	 compensatory	 locus	was	
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(from	 Table	 2)	 or	 explore	 known	 compensatory	 effects	 using	 a	 test	 of	 non-random	
association	 to	detect	 the	 frequent	co-occurrence	of	mutations	 in	pairs	of	 loci	 (Fisher	
exact	test,	P-value	cut-off	<10-8)	(Supplementary	table	5).	Deep	phylogenetic	mutations	









was	 marginal	 evidence	 for	 pyrG	 (lineage	 4,	 P=0.00016)27	 and	 Rv0565c	 (lineage	 2,	
P=0.00027)	with	ethA	 (ETH)28	 (Supplementary	 table	 6).	 Follow-up	 investigations	will	
need	 to	 determine	 whether	 mutations	 in	 these	 loci	 have	 an	 impact	 on	 the	MIC	 or	
function	as	compensatory	mechanisms.	
	
Overall,	 the	 GWAS	 approach	 was	 effective	 at	 detecting	 known	 drug	 resistance	
determinants	 and	 epistatic	 (gene-gene)	 relationships	 and	 identified	 novel	 ones	 that	








The	 rpoB	 locus	 showed	 the	 strongest	 association	 with	 RIF	 resistance,	 but	 the	
compensatory	 effects	 of	 rpoC	 and	 rpoA	were	 also	 evident	 through	 homoplasy	 SNP	
analysis.	As	previously	 reported	non-synonymous	 SNPs	 in	 rpoC	 (272	 identified)	were	






inhA,	 encoding	 the	molecular	 target	of	 isoniazid32	 and	 the	Rv1482c-fabG1	 intergenic	
region	 harbouring	 its	promoter,	 showed	 strong	 associations	with	 INH	 and	 ETH,	with	
greater	effects	in	the	former.	In	addition,	oxyR'-ahpC	 intergenic	associated	mutations	
(20	detected)	were	found	in	the	presence	of	katG	polymorphisms	(28),	supporting	its	
role	 as	 a	 compensatory	mechanism.	 	 For	 ethionamide,	 the	ethA	 locus,	 encoding	 the	
drug-metabolising	 enzyme	was	 found	 to	 be	 associated	 with	 resistance	 as	 described	





Mutations	 in	 the	 embCAB	 operon,	 which	 encodes	 for	 enzymes	 involved	 in	 the	




associated	 in	our	analysis	demonstrating	a	 role	 in	clinical	 samples	 too	across	all	 four	





was	 a	 target	 of	 independent	 mutation,	 consistent	 with	 its	 established	 role35.	
Additionally,	many	 low	 frequency	 SNPs	were	 reported	 across	 the	whole	 gene	which	






GWAS.	Mutations	 in	 rpsL	 are	 known	 to	 lead	 to	 high	 levels	 of	 STM	 resistance38,	 and	
accordingly	we	observed	high	odds	ratios	indicative	of	high	penetrance	in	association	
signals	in	this	locus	(Figure	3).	In	contrast,	candidate	rrs	and	gid	gene	polymorphisms	
showed	weaker	 signals	 (lower	 odds	 ratio)	 in	 the	 overall	 GWAS,	 which	 concurs	 with	
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existing	 evidence	 that	gid	 and	 rrs	mutations	 confer	 low	 levels	 of	 resistance38.	When	
considering	the	odds	ratios	across	all	SNP-drug	associations,	those	from	rrs	and	gid	were	
much	 lower	 on	 average	 than	 those	 from	 pncA	 (PZA)	 and	 katG	 (INH)	 (Figure	 3).	This	
analysis	 demonstrates	 a	 potential	 utility	 of	 using	 odds	 ratios	 and	 their	 statistical	





















exhibit	 increased	 resistance	 to	 CYS12	 and	 harboured	multiple	 homoplastic	mutations	
including	 Phe4Leu,	 Lys113Arg	 and	 Met343Thr.	 In	 a	 previous	 study,	 the	 Met343Thr	
mutation	was	detected	in	an	XDR-TB	strain	that	had	been	exposed	to	CYS	treatment,	
predicted	to	alter	the	protein	structure	of	Alr,	and	therefore	it	was	hypothesised	to	be	
involved	 in	 CYS	 resistance44.	 To	 further	 understand	 the	 functional	 impact	 of	 the	
mutations	 found	 in	alr	we	modelled	 the	 effect	 of	 these	 variants	 using	 the	 available	
crystal	 protein	 structure	 (PDB	1XFC,	Supplementary	 figure	3).	Mutations	 in	alr	were	
found	 to	differ	 in	 their	 proximity	 to	 the	CYS	binding	 site	 and	 their	 effect	 on	protein	
stability	and	ligand	binding	(Supplementary	table	7).	The	Met343Thr	mutation	(found	
in	12	susceptible	and	2	resistant	isolates)	was	predicted	to	have	more	drastic	effect	on	
protein	 structure	 compared	 to	 Lys113Arg,	 the	 most	 frequent	 mutation	 among	 CYS	
resistant	 isolates	 (in	 7	 susceptible	 and	 23	 resistant	 isolates).	 There	 appears	 to	 be	 a	













expression	 by	 18-fold	 relative	 to	 wild-type	 promoter	 although	 no	 link	 with	 PAS	
resistance	 was	 made20.	 Of	 3	 PAS	 resistance	 strains	 with	 the	 G-16A	 thyX	 promoter	








to	 susceptible	 strains	 revealed	 only	 one	 significant	 annotation	 cluster	with	 17.7-fold	





genes	 and	 operons	 (Supplementary	 table	 8,	 Supplementary	 data	 1).	 The	 candidate	
genes	differed	in	their	abundance	of	small	indels,	reflecting	their	essentiality	for	survival:	
drug	targets	had	less	density	of	indels	whereas	drug-metabolising	enzymes	had	a	greater	
density.	 For	 example,	 the	pncA	 gene	was	 the	most	 polymorphic	 coding	 region	 (PZA,	
44.72	indels	/kb)	while	the	least	polymorphic	was	rpoB	(RIF,	2.3	indels	/kb).	Although,	
the	majority	 of	 small	 indels	 (83%)	 in	 the	 candidate	 regions	were	 1bp	 in	 length	 and	
caused	frame-shifts,	the	indels	in	rpoB	inserted	or	deleted	whole	codons,	i.e.	they	did	
not	 cause	 a	 shift	 in	 the	 codon	 reading	 frame.	 Indels	 in	 rpoB,	 pncA	 and	 the	 embAB	
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promoter	 region	 were	 associated	 with	 MDR-TB,	 XDR-TB	 and	 their	 respective	
targets/activators.	 Indels	 in	 ethA	 were	 associated	 with	 ETH	 and	 XDR-TB	 resistance.	
Similarly,	gid	indels	were	associated	with	STM	as	expected.	
	














statistical	 significance	 (P<0.05).	 These	 genes	 activate	 pro-drugs,	 and	 none	 are	







We	sought	 to	establish	 if	any	of	 the	mutations	 found	 in	association	and	homoplastic	
analysis	increased	the	predictability	of	individual	drug	resistance	phenotypes	(Table	3).	
We	 used	 the	 reported	 phenotypic	 drug	 susceptibility	 test	 result	 as	 the	 reference	
standard	to	calculate	the	sensitivity	and	specificity	for	mutation-resistance	predictions.	












largest	 and	most	 geographically	 widespread	 study	 to	 date,	 encompassing	 a	 total	 of	








known	 mutations	 underlying	 MDR-TB16.	 However,	 the	 incompleteness	 of	 first-	 and	
second-line	 drug	 resistance	 outcomes	 meant	 association	 analysis	 to	 detect	 novel	
mutations	 was	 not	 possible.	 Whilst	 resistant	 phenotypes	 may	 be	 imputed	 from	
established	 resistance	causing	mutations,	 inferring	 susceptibility	 to	a	drug	cannot	be	
assumed	 in	 the	 absence	 of	 corroborating	 evidence19.	 The	 completeness	 of	 our	
susceptibility	test	data	meant	that	both	GWAS	and	homoplasy-based	methods	could	be	




established	 resistance	 loci	 and	 compensatory	 relationships,	 thereby	 confirming	 the	
authenticity	and	robustness	of	the	approach.	It	also	revealed	several	recently	discovered	
loci	(folC,	ubiA,	thyX-hsdS.1,	thyA,	alr,	ald,	dfrA-thyA),	new	epistatic	relationships	(pncA	
with	 pncB2,	 and	 thyA	 with	 thyX-hsdS.1)	 and	 efflux	 pumps	 represented	 by	 the	 ABC	
transporters	 drrA	 and	 Rv2688c	 associated	 with	 drug	 resistance.	 The	 novel	 genetic	
markers	associated	with	resistance	identified	in	this	GWAS	included	SNPs	in	the	ethA	
and	 thyX	 promoters,	 small	 indels	 in	 pncA	 and	 ald,	 and	 large	 deletions	 in	 pro-drug	
activators	 such	 as	 ethA	 and	 katG.	 These	 loci	 warrant	 functional	 follow-up	 and	
characterization	 studies	 to	 fully	 elucidate	 their	 role	 in	 treatment	 failure.	 	 The	






























methods	 have	 a	 degree	 of	 uncertainty,	 especially	 close	 to	 the	 threshold45.	 Testing	
against	 a	 range	 of	 drug	 concentrations	 to	 establish	 the	 minimum	 inhibitory	
concentration	 (MIC)	 is	 a	preferred	approach	but	 is	 not	 routinely	undertaken42.	Most	
resistance	 is	 of	 a	 high	 level	 when	 strains	 can	 survive	 high	 drug	 concentrations	 but	
intermediate	and	low	levels	of	resistance	are	also	reported	for	some	drugs,	and	in	such	










was	 the	 sampling	methodology	 since	 collection	of	 the	 isolates	was	not	 controlled	or	
systematic	 and	 resistant	 isolates	were	 not	 evenly	 distributed	 across	 collection	 sites.		
However,	within	our	study	population	we	covered	the	four	major	Mtb	lineages	across	5	
continents	 and	 sampled	 multiple	 geographical	 regions,	 allowing	 us	 to	 observe	
differences	in	the	prevalence	of	drug	resistance	mutations	and	mechanisms.	Some	of	










personalised	 treatment	 offers	 improved	 rates	 of	 cure48.	 Next	 generation	 sequencing	
offers	a	comprehensive	assessment	and	may	be	used	to	guide	treatment48.	Although	
such	technology	is	currently	being	implemented	in	some	low	burden	countries	such	as	







undergone	 drug	 susceptibility	 testing	 by	 phenotypic	 methods.	 These	 isolates	
represented	multiple	 populations	 from	different	 geographic	 areas,	 and	 all	 four	main	
lineages	(1	to	4)	(Supplementary	table	1).	The	2,637	samples	not	previously	sequenced	
were	Illumina	sequenced	generating	paired-end	reads	of	at	least	50	bp	with	at	least	50-
fold	 genome	 coverage.	 The	 analytical	 workflow	 for	 the	 raw	 sequence	 data	 is	
summarised	in	Supplementary	figure	5.	The	new	and	archived	raw	sequence	data	were	
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aligned	 to	 the	H37Rv	 reference	 genome	 (Genbank	 accession	 number:	NC_000962.3)	
using	 the	BWA	mem	algorithm49.	 The	SAMtools/BCFtools50	 and	GATK51	 software	was	
used	to	call	SNPs	and	small	indels	using	default	options.	The	GATK	parameters	used	are	






missing	 genotype	 calls	were	 removed.	 This	 quality	 control	 step	was	 implemented	 to	
remove	samples	with	bad	quality	genotype	calls	due	to	poor	depth	of	coverage	or	mixed	
infections.	The	 final	dataset	 included	6,465	 isolates	and	102,160	genome-wide	SNPs.	
Delly2	software52	was	used	to	find	large	deletions.	All	large	deletions	were	confirmed	
using	 localised	de	novo	assembly,	and	those	found	 in	association	analysis	 (dfrA/thyA,	
pncA,	ethA/ethR,	katG)	confirmed	using	PCR.		
Phenotypic	drug	susceptibility	testing	





1996	 and	 2010)	 and	 others	 were	 extracted	 specifically	 for	 this	 study.	 Information	
regarding	isolates	with	previously	reported	sequence	data	was	derived	from	published	
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materials.	 Isolates	were	 classed	 as	 resistant	 or	 susceptible	 to	 a	 drug	on	 the	basis	 of	






drug.	 Drug	 susceptibility	 testing	 was	 mainly	 undertaken	 in	 local	 laboratories	
participating	in	the	WHO	supranational	laboratory	network	using	the	recognised	testing	




initially	 tested	 for	 resistance	 to	 rifampicin	 and	 isoniazid	 using	 the	 Microscopic	
Observation	Drug	Susceptibility	assay	(MODS)56	at	the	Universidad	Peruana	Cayetano	
Heredia	(UPCH)	prior	to	transfer	to	the	national	reference	laboratory	for	further	testing.	
In	 Peru	 susceptibility	 to	 pyrazinamide	 (PZA)	 was	 assessed	 by	 the	 Wayne	 assay;	 a	
colorimetric	biochemical	test	during	which	PZA	is	hydrolysed	to	free	pyrazinoic	acid57.	








For	 Lowenstein-Jensen	 drug	 concentrations	 used	 were	 for	 streptomycin	 4.0	 μg/ml,	
isoniazid	 0.2	 μg/ml,	 rifampicin	 40.0	 μg/ml,	 ethambutol	 2.0	 μg/ml,	 capreomycin	 40.0	




The	 best-scoring	 maximum	 likelihood	 phylogenetic	 tree	 rooted	 on	 Mycobacterium	
canettii	was	 constructed	 by	RAxML	 software59	 (10,000	 bootstrap	 samples)	 using	 the	
102,160	high	quality	SNP	sites.	Spoligotypes	were	inferred	in	silico	using	SpolPred60,	and	
strain-types	 determined	 using	 lineage-specific	 SNPs6.	 Further	 population	 structure	
assessment	was	performed	using	principal	components	analysis	(Supplementary	figure	
3),	which	 clustered	 samples	 by	 genotype	 congruent	with	 the	 phylogenetic	 tree.	 The	
principal	components	were	calculated	from	a	SNP	pair-wise	distance	matrix	between	











matrix	 as	 a	 random	 effect	 to	 account	 for	 highly	 related	 samples	 and	 fine-scale	
population	structure	due	to	potential	outbreaks15,	and	were	implemented	in	GEMMA	
(v.1.1.2)	software61.	To	minimise	any	co-resistance	between	drugs,	and	we	adjusted	for	
the	 presence	 of	 other	 resistance	 in	 the	 regression	 models.	 Statistical	 significance	
thresholds	 to	 account	 for	 multiple	 testing	 were	 established	 using	 a	 permutation	
approach	 that	 sorted	 phenotypic	 test	 data	 without	 replacement	 and	 re-performed	
GWAS	 analysis	 (10,000	 times).	 The	 determined	 P-value	 threshold	 was	 1x10-5.	 All	
statistical	 analysis	 was	 performed	 using	 R	 software.	 To	 identify	 SNPs	 enriched	 by	
convergent	 evolution,	 the	phyC	 approach	was	 employed10	 using	 the	 implementation	
made	available	in	a	previous	study62.	Any	potential	co-resistance	effects	were	dissected	
through	 consulting	 gene	 annotation	 and	 published	 literature	 to	 report	 the	 most	
plausible	role	 in	drug	resistance.	Additionally,	 long	branches	 in	 the	phylogenetic	 tree	
leading	up	to	clades	enriched	with	drug	resistant	isolates	leads	to	spurious	associations.	














Apo	 crystal	 structures	 for	 alr	 were	 downloaded	 from	 the	 Protein	 Data	 Bank	
(PDBe1XFC63)	 and	 then	 subjected	 to	 modelling	 of	 missing	 residues,	 WinCOOT	
regularisation,	 and	 removal	 of	 pyridoxal	 5ʹ-phosphate	 from	 both	 chains.	 The	mCSM	
(http://structure.bioc.cam.ac.uk/mcsm)	 and	 DUET	 (http://structure	
.bioc.cam.ac.uk/duet)	 web	 servers	 were	 used	 to	 assess	 changes	 in	 protein	 stability,	
mCSM-PPI	(http://structure.bioc.cam.ac.uk/mcsm_ppi)	to	quantify	effects	on	protein-





All	 raw	sequencing	data	are	available,	and	 the	study	accession	numbers	are	 listed	 in	
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MDR-TB	vs.	Susc.	 Rv0667	 rpoB	 1.98E-139	 159	 7	(0)	 6	 8	
MDR-TB	vs.	Susc.	 Rv1908c	 katG	 2.72E-110	 177	 12	(9)	 1	 1	
MDR-TB	vs.	Susc.	 Rv1482c-Rv1483	 Rv1482c-fabG1	 1.18E-25	 8	 0	 1	 1	
MDR-TB	vs.	Susc.	 Rv3795	 embB	 1.23E-18	 168	 2	(0)	 1	 9	
MDR-TB	vs.	Susc.	 Rv1484	 inhA	 3.13E-18	 9	 0	 2	 0	
MDR-TB	vs.	Susc.	 Rv3793-Rv3794	 embC-embA	 1.85E-13	 6	 6	 1	 3	
MDR-TB	vs.	Susc.	 Rv0682	 rpsL	 2.96E-13	 6	 0	 0	 2	
MDR-TB	vs.	Susc.	 Rv3919c	 gid	 5.22E-11	 137	 26	(26)	 0	 1	
MDR-TB	vs.	Susc.	 Rv2427A-Rv2428	 oxyR'-ahpC	 2.51E-10	 17	 3	 0	 3	
MDR-TB	vs.	Susc.	 Rv0721	 rpsE	 8.10E-08	 24	 0	 0	 0	
MDR-TB	vs.	Susc.	 Rv2043c	 pncA	 1.32E-06	 117	 25	(22)	 0	 1	
XDR-	vs.	MDR-TB	 Rv0006	 gyrA	 5.10E-30	 147	 0	 2	 4	
XDR-	vs.	MDR-TB	 rrs	 rrs	 5.30E-06	 91	 4	 1	 2	
XDR-TB	vs.	Susc.	 Rv0667	 rpoB	 3.04E-203	 159	 7	(0)	 7	 5	
XDR-TB	vs.	Susc.	 Rv2043c	 pncA	 4.52E-143	 117	 25	(22)	 2	 0	
XDR-TB	vs.	Susc.	 Rv3795	 embB	 6.17E-85	 168	 2	(0)	 4	 4	
XDR-TB	vs.	Susc.	 Rv1908c	 katG	 7.38E-83	 177	 12	(9)	 1	 1	











XDR-TB	vs.	Susc.	 Rv3793-Rv3794	 embC-embA	 2.85E-49	 6	 6	 2	 2	
XDR-TB	vs.	Susc.	 Rv0682	 rpsL	 1.05E-40	 6	 0	 1	 2	
XDR-TB	vs.	Susc.	 rrs	 rrs	 4.66E-29	 91	 4	 2	 3	
XDR-TB	vs.	Susc.	 Rv1144-Rv1145	 Rv1144-mmpL13a	 6.70E-08	 33	 4	 1	 0	
XDR-TB	vs.	Susc.	 Rv1484	 inhA	 6.10E-29	 9	 0	 2	 0	
XDR-TB	vs.	Susc.	 Rv0006	 gyrA	 1.27E-25	 147	 0	 4	 4	
XDR-TB	vs.	Susc.	 Rv0668	 rpoC	 9.57E-19	 153	 1	(0)	 2	 0	
XDR-TB	vs.	Susc.	 Rv2427A-Rv2428	 oxyR'-ahpC	 7.20E-15	 17	 3	 0	 0	
XDR-TB	vs.	Susc.	 Rv2936		 drrA	 1.46E-09	 19	 0	 1	 0	
XDR-TB	vs.	Susc.	 Rv3854c	 ethA	 2.04E-11	 163	 38	(35)	 0	 0	
XDR-TB	vs.	Susc.	 Rv3854c-Rv3855	 ethA-ethR	 5.87E-06	 12	 0	 1	 0	
XDR-TB	vs.	Susc.	 Rv2416c-Rv2417c	 eis-Rv2417c	 5.88E-06	 12	 1	 0	 1	































Isoniazid	 Rv1908c	 katG	 6.40E-114	 177	 12	(9)	 1	 3	
Isoniazid	 Rv1482c-Rv1483	 Rv1482c-fabG1	 8.01E-62	 8	 0	 2	 2	
Isoniazid	 Rv2427A-Rv2428	 oxyR'-ahpC	 3.48E-28	 17	 3	 0	 3	
Isoniazid	 Rv1484	 inhA	 1.44E-07	 9	 0	 1	 1	
Rifampicin	 Rv0667	 rpoB	 2.87E-245	 159	 7	(0)	 6	 9	
Rifampicin	 Rv0668	 rpoC	 2.65E-08	 153	 1	(0)	 0	 9	
Ethambutol	 Rv3795	 embB	 4.67E-115	 168	 2	(0)	 4	 10	
Ethambutol	 Rv3793-Rv3794	 embC-embA	 1.62E-44	 6	 6	 2	 5	
Ethambutol	 Rv2820c	 .	 1.30E-10	 16	 0	 1	 0	
Ethambutol	 Rv3806c	 ubiA	 1.36E-10	 47	 0	 0	 2	
Ethambutol	 Rv3300c	 .	 8.02E-08	 39	 5	(3)	 0	 0	
Ethionamide	 Rv1482c-Rv1483	 Rv1482c-fabG1	 4.78E-11	 8	 0	 1	 2	
Ethionamide	 Rv1484	 inhA	 7.60E-07	 9	 0	 1	 0	
Pyrazinamide	 Rv2043c	 pncA	 3.18E-110	 117	 25	(22)	 2	 1	
Pyrazinamide	 Rv2043c-Rv2044c	 pncA-Rv2044c	 7.74E-29	 4	 1	 1	 1	
Streptomycin	 Rv0682	 rpsL	 1.57E-82	 6	 0	 2	 2	
Streptomycin	 Rv3919c	 gid	 1.51E-26	 137	 26	(26)	 0	 1	













Amikacin	 rrs	 rrs	 2.68E-46	 91	 4	 1	 1	
Kanamycin	 rrs	 rrs	 7.42E-38	 91	 4	 2	 2	
Kanamycin	 Rv2416c-Rv2417c	 eis-Rv2417c	 3.53E-18	 12	 1	 1	 1	
Capreomycin	 rrs	 rrs	 2.12E-37	 91	 4	 1	 1	
Capreomycin	 Rv2172c-Rv2173	 Rv2172c-idsA2	 2.93E-06	 18	 0	 2	 0	
Ciprofloxacin	 Rv0006	 gyrA	 9.30E-43	 147	 0	 2	 2	
Moxifloxacin	 Rv0006	 gyrA	 3.51E-22	 147	 0	 2	 5	
Ofloxacin	 Rv0006	 gyrA	 3.88E-49	 147	 0	 3	 6	
D-Cycloserine	 Rv3423c	 alr	 1.26E-13	 57	 0	 1	 0	
D-Cycloserine	 Rv0342	 iniA	 3.37E-08	 76	 13	(12)	 1	 0	
PAS	 Rv2764c	 thyA	 3.74E-10	 36	 4	(4)	 0	 0	
PAS	 Rv2754c-Rv2755c	 thyX-hsdS.1	 4.27E-07	 21	 0	 1	 1	
This	 table	shows	 loci	 (protein	and	RNA	coding	and	 intergenic	 regions)	associated	with	 resistance	 to	 individual	drugs	 (P-value	<	1x10-5).	The	
column	labelled	as	‘NS	SNPs’	show	the	number	of	non-synonymous	SNPs	in	the	genes;	the	column	‘Indels	(frame.)’		refers	to	the	number	of	
small	indels	resulting	in	frameshifts	in	the	genes;	‘Assoc.	SNPs’	is	the	number	of	SNPs	identified	by	GWAS,	and	‘PhyC	SNPs’	refers	to	the	number	






	 TBDR	panel	 +	SNPs	 +	small	indels	+	SNPs	
+	big	deletions	+	small	indels	+	
SNPs	
Drug	 Sens.	 Spec.	 Sens.	 Spec.	 Sens.	 Spec.	 Sens.	 Spec.	
Isoniazid	 88	 97	 88	 97	 89	 97	 89	 97	
Rifampicin	 91	 98	 91	 98	 92	 98	 92	 98	
Ethambutol	 88	 92	 88	 92	 88	 92	 88	 92	
Ethionamide	 75	 75	 75	 73	 82	 70	 86	 70	
Pyrazinamide	 56	 98	 56	 98	 59	 98	 62	 98	
Streptomycin	 75	 93	 76	 93	 79	 91	 79	 91	
Amikacin	 83	 96	 83	 96	 85	 93	 85	 93	
Kanamycin	 86	 98	 86	 98	 86	 98	 86	 98	
Capreomycin	 73	 96	 73	 96	 80	 95	 80	 95	
Ciprofloxacin	 88	 98	 88	 98	 88	 98	 88	 98	
Moxifloxacin	 84	 90	 84	 90	 84	 90	 84	 90	
Ofloxacin	 83	 93	 83	 93	 83	 93	 83	 93	
D-Cycloserine	 -	 -	 55	 92	 61	 90	 61	 90	
PAS	 10	 100	 20	 99	 40	 94	 65	 94	
	 	 	 	 	 	 	 	 	
MDR-TB	 88	 99	 88	 99	 88	 99	 89	 99	















Population	 N	 lineage	1	 lineage2	 lineage3	 lineage4	 Susc.	 DR	 MDR-TB	 XDR-TB	 ENA	Accession	
Canada	 11	 0	 0	 0	 11	 11	 0	 0	 0	 SRA020129	
Brazil	 108	 0	 0	 0	 108	 4	 9	 72	 23	 PRJEB10385	
Colombia	 15	 0	 0	 0	 15	 0	 0	 14	 1	 PRJEB10385	
Peru	 78	 0	 6	 0	 72	 25	 32	 17	 4	 PRJEB10385	
Bulgaria	 2	 0	 0	 0	 2	 0	 0	 2	 0	 PRJEB10385	
Germany	 20	 0	 0	 0	 20	 20	 0	 0	 0	 ERP006619	
Portugal	 183	 0	 20	 1	 162	 19	 71	 60	 33	 ERP002611	
Russia	 2	 0	 2	 0	 0	 1	 1	 0	 0	 ERP00192	
China	 161	 0	 122	 2	 37	 44	 0	 71	 46	 SRP018402	
Vietnam	 43	 16	 19	 0	 8	 22	 6	 8	 7	 PRJEB10385	
India	 3	 0	 0	 2	 1	 1	 0	 2	 0	 PRJEB10385	
Pakistan	 42	 5	 0	 33	 4	 5	 0	 0	 37	 ERP008770	
Saudi	Arabia	 74	 10	 11	 18	 35	 57	 6	 11	 0	 PRJEB10385	
Malawi	 1646	 264	 71	 195	 1116	 1526	 112	 8	 0	 ERP000436	
South	Africa	 594	 8	 231	 15	 340	 308	 93	 83	 110	 PRJEB10385	
Uganda	 45	 1	 1	 13	 30	 3	 2	 39	 1	 ERP000520	
WHO*	 138	 14	 34	 4	 86	 35	 51	 52	 0	 ERP013054	
Mixed**	 96	 4	 38	 4	 50	 96	 0	 0	 0	 	ERP001037	
UK	 3204	 295	 466	 706	 1737	 2500	 343	 351	 10	 	ERX511672		
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Population	 N	 lineage	1	 lineage2	 lineage3	 lineage4	 Susc.	 DR	 MDR-TB	 XDR-TB	 ENA	Accession	
Total	 6465	 617	 1021	 993	 3834	 4677	 726	 790	 272	 	


















Drug	 Lineage	1	 Lineage	2	 Lineage	3	 Lineage	4	 Total	Resistant	 (%)	
Rifampicin	(RIF)	 26/609	 549/928	 78/985	 488/3529	 1141	 -18.9	
Isoniazid	(INH)	 87/608	 569/938	 157/985	 723/3546	 1536	 -25.3	
Ethambutol	(EMB)	 16/403	 357/858	 36/839	 236/2707	 645	 -13.4	
Pyrazinamide	(PZA)	 20/393	 261/638	 39/796	 164/2259	 484	 -11.9	
Streptomycin	(STR)	 23/227	 450/718	 44/293	 369/1957	 886	 -27.7	
Capreomycin	(CAP)	 Jan-15	 125/347	 Oct-63	 91/579	 227	 -22.6	
Amikacin	(AMK)	 May-16	 128/254	 28/70	 66/546	 227	 -25.6	
Kanamycin	(KAN)	 May-17	 128/320	 28/63	 88/506	 249	 -27.5	
Moxifloxacin	
(MOX)	 0/15	 66/232	 Feb-38	 20/351	 88	 -13.8	
Ofloxacin	(OFL)	 01-Feb	 150/281	 Jan-22	 135/388	 287	 -41.4	
Ethionamide	(ETH)	 01-Jun	 102/273	 Feb-34	 117/284	 222	 -37.2	
Ciprofloxacin	(CIP)	 May-41	 Feb-24	 32/101	 20/160	 59	 -18.1	
PAS		 0/0	 7/119	 0/0	 13/136	 20	 -7.8	









Lineage	1	 Lineage	2	 Lineage	3	 Lineage	4	
Total	 (%)	
N	(%)	 N	(%)	 N	(%)	 N	(%)	
Susceptible	 516	(83.6)	 408	(40.0)	 819	(82.5)		 2935	(76.6)	 4678	 -72.4	
Drug	resistant	 77	(12.5)	 78	(7.6)	 102	(10.3)	 407	(10.6)	 664	 -10.3	
MDR-TB	 18	(2.9)	 393	(38.5)	 43	(4.3)	 380	(9.9)	 834	 -12.9	
XDR-TB	 6	(1.0)	 142	(13.9)	 29	(2.9)	 112	(2.9)	 289	 -4.5	
Total	 617	 1021	 993	 3834	 6465	 	



















katG	 S315T	 0.4	 40.5	 79.8	 78	
rpoB	 S450L	 0.1	 25.6	 67	 52	
rpsL	 K43R	 0.5	 16	 45.8	 25.6	
embB	 M306V	 0	 10.5	 34.9	 39.4	
rrs	 A1401G	 0	 7.4	 11.7	 63.4	
Rv1482c-fabG1	 C-15T	 0.3	 25	 11.5	 31.9	
embB	 M306I	 0.3	 7.2	 22.1	 37.4	
gyrA	 A90V	 0	 2.5	 3.1	 32.7	
rrs	 A514C	 0.2	 3.2	 5.7	 27.2	
gyrA	 D94G	 0.3	 5.6	 2	 27.6	
gid	 L79S	 0	 1.2	 2.6	 22	
rpoB	 L452P	 0	 1.4	 4.5	 19.7	
ethA-ethR	 T-65C	 0	 0.7	 5.4	 18.9	
Rv1482c-fabG1	 T-8A	 0	 1.2	 3.7	 19.3	
rpoB	 D435V	 0	 2.5	 6.3	 13.8	
rpoB	 D435G	 0	 0.3	 0.3	 19.3	
ubiA	 V188A	 0	 0.1	 0.3	 18.5	
rpoB	 I1106T	 0	 0.2	 0	 18.5	
inhA	 S94A	 0	 7.6	 1.2	 7.5	
Rv1482c-fabG1	 G-17T	 0	 0.8	 1.3	 11.4	
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Supplementary	table	3	-	continued	
Gene	 Mutation	 Susceptible	%	 DR		 MDR-TB	allele	frequency	%	
XDR-TB	allele	
frequency	%	
inhA	 I194T	 0	 4	 1.9	 7.5	
ubiA	 A249T	 0	 0.6	 0.9	 10.6	
PPE52-nuoA	 G-314T	 0	 0.7	 1.2	 10.2	
eis-Rv2417c	 C-10T	 0	 2.5	 3.9	 5.5	
rpsL	 K88R	 0.1	 3.8	 5.4	 2.4	
iniA	 H42R	 0	 0.6	 0.7	 10.2	
gyrA	 D94A	 0	 1.9	 1.3	 8.3	
alr	 L113R	 0	 0.7	 0.7	 9.8	
pncA	 Q10*	 0	 1.1	 7.3	 2.8	
embB	 Q497R	 0	 1.7	 6.1	 2.4	
rpoB	 D435Y	 0	 1.5	 3.2	 4.7	
rpoB	 H445Y	 0	 2.7	 3.7	 2	
gyrA	 S91P	 0.1	 1.8	 1.3	 5.1	
embC-embA	 C-12T	 0	 0.4	 3.7	 3.9	
embB	 G406A	 0	 0.8	 3.4	 3.5	
pncA	 Q10P	 0	 0.3	 5.8	 1.6	
eis-Rv2417c	 G-12A	 0	 0.3	 6	 0.8	
embC-embA	 C-16T	 0	 1.8	 2	 3.1	
embC-embA	 C-16G	 0	 0.6	 1.6	 4.3	
rpoB	 H445D	 0	 2.6	 2.9	 0.8	




Gene	 Mutation	 Susceptible	%	 DR		 MDR-TB	allele	frequency	%	
XDR-TB	allele	
frequency	%	
thyX-hsdS.1	 G-16A	 0	 1.4	 1.8	 2.8	
rpoB	 L731P	 0	 2.1	 1	 2.8	
embB	 G406D	 0	 1.7	 3.2	 0.8	
pncA	 V125G	 0	 2	 1.3	 2.4	
embC-embA	 C-11A	 0	 1.3	 0.7	 3.5	
katG	 S315R	 0	 1.7	 0.6	 3.1	
pncA-Rv2044c	 T-11C	 0	 0.7	 3.4	 1.2	
katG	 S315N	 0	 1.7	 1.9	 1.6	
gyrA	 D94N	 0.1	 0.8	 0.3	 3.9	
embB	 M423T	 0	 2	 0.7	 2.4	
gid	 A80P	 0	 2	 0.7	 2.4	
embC-embA	 G-43C	 0	 0.3	 2	 2.4	
embB	 D354A	 0	 0.7	 2.3	 1.6	
Rv2172c-idsA2	 A-65G	 0	 1.3	 0.6	 2.8	
embC-embA	 C-12A	 0	 1.3	 0.6	 2.8	
embB	 P397T	 0	 1.3	 0.6	 2.8	
rrs	 C517T	 0	 0.8	 1.9	 1.6	
eis-Rv2417c	 G-14A	 0	 0.3	 1.2	 2.8	
embB	 G406S	 0	 0.7	 2.2	 1.2	
rpoB	 H445R	 0.1	 0.5	 1.9	 1.6	




Gene	 Mutation	 Susceptible	%	 DR		 MDR-TB	allele	frequency	%	
XDR-TB	allele	
frequency	%	
oxyR’-ahpC	 G-48A	 0	 0.7	 0.7	 2.4	
alr	 M343T	 0	 0.9	 0.4	 2.4	
rpoB	 S450W	 0	 0.8	 1.9	 0.4	
oxyR’-ahpC	 C-52T	 0.1	 0.6	 1.6	 0.8	
rpoB	 H445L	 0	 0.7	 1.2	 1.2	
pncA	 V139M	 0	 0.4	 0.1	 2.4	
rpoB	 H445N	 0.1	 2.1	 0.4	 0	
rpoB	 L430P	 0.1	 1.1	 1.3	 0	
embC-embA	 C-8T	 0	 0.2	 0.7	 1.6	
rpoB	 I491F	 0.2	 2.2	 0	 0	
pncA	 W68*	 0	 0.2	 1.5	 0.8	
Rv1482c-fabG1	 T-8C	 0.4	 0.4	 0.9	 0.8	
pncA	 Q141P	 0	 0.7	 0.9	 0.8	
gyrA	 D94H	 0	 0.2	 0.7	 1.2	
rrs	 A514T	 0	 1.3	 0.3	 0.4	








Lineage	 Gene	 Position	 Drug	 Min	P-value	 Susc.	 DR	 MDR-TB	 XDR-TB	
4	 gyrA	 7570	 X	v	M	or	SUS	 1.51E-15	 0.001	 0.024	 0.032	 0.329	
4	 gyrA	 7572	 X	v	SUS	 8.92E-21	 0.001	 0.018	 0.013	 0.051	
3,4	 gyrA	 7581	 X	v	SUS	 1.17E-21	 0.001	 0.016	 0.016	 0.103	
4	 gyrA	 7582	 KAN	 4.40E-09	 0.004	 0.076	 0.034	 0.359	
2	 gyrA	 7582	 X	v	M	 1.70E-08	 0.004	 0.076	 0.034	 0.359	
4	 gyrA	 7582	 X	v	M	or	SUS	 8.52E-07	 0.004	 0.076	 0.034	 0.359	
2	 rpoB	 760314	 M	v	SUS	 4.92E-22	 0	 0.004	 0.006	 0.004	
3	 rpoB	 761108	 X	v	SUS	 3.44E-14	 0	 0.001	 0.003	 0.016	
2-4	 rpoB	 761109	 M	or	X	v	SUS,	RMP	 3.34E-28	 0	 0.015	 0.032	 0.048	
3,4	 rpoB	 761110	 X	v	M,	X	or	M	v	SUS,	
RMP	
3.35E-85	 0	 0.029	 0.066	 0.337	
1,2,4	 rpoB	 761139	 X	or	M	v	SUS	 3.46E-16	 0.001	 0.076	 0.071	 0.028	
1-4	 rpoB	 761139	 RMP	 1.61E-97	 0.001	 0.076	 0.071	 0.028	
1,2,4	 rpoB	 761140	 M	or	X	v	SUS,	RMP	 2.66E-17	 0.001	 0.01	 0.034	 0.028	
1-4	 rpoB	 761155	 M	or	X	v	SUS,	RMP	 1.17E-219	 0.001	 0.267	 0.695	 0.524	
2,4	 rpoB	 761161	 M	or	X	v	SUS	 9.67E-18	 0	 0.013	 0.044	 0.197	
4	 rpoB	 763123	 X	v	M	or	SUS	 1.13E-17	 0	 0.002	 0	 0.185	
3	 rpoC	 764666	 X	or	M	v	SUS,	RMP	 3.74E-29	 0	 0.003	 0.004	 0.016	




Lineage	 Gene	 Position	 Drug	 Min	P-value	 Susc.	 DR	 MDR-TB	 XDR-TB	
4	 rpoC	 766823	 X	v	SUS	 1.64E-06	 0	 0.013	 0.006	 0.028	
1	 rpoC	 767123	
MDR	or	XDR	v	SUS,	
RMP	 3.91E-24	 0	 0.003	 0.015	 0.016	
2-4	 rpsL	 781687	
MDR	or	XDR	v	SUS,	
STM	 1.65E-45	 0.005	 0.159	 0.458	 0.257	
2-4	 rpsL	 781822	 STM	 4.16E-10	 0.002	 0.041	 0.061	 0.024	
1	 rrs	 1472358	 STM	 5.12E-06	 0	 0.010	 0.001	 0	
4	 rrs	 1472359	 STM	 2.66E-13	 0.002	 0.047	 0.061	 0.276	
3,1	 rrs	 1472359	 M	or	X	v	SUS	 5.71E-18	 0.002	 0.047	 0.061	 0.276	
1	 rrs	 1472362	 M	or	X	v	SUS,	STM	 3.52E-71	 0	 0.009	 0.019	 0.016	
3	 rrs	 1472751	 X	v	SUS	 2.28E-10	 0	 0.004	 0.006	 0.004	
2,4	 rrs	 1473246	 AMK,	CAP,	KAN	 6.68E-42	 0	 0.075	 0.120	 0.651	
3	 rrs	 1473246	 STM	 3.05E-09	 0	 0.075	 0.120	 0.651	
2-4	 rrs	 1473246	 X	v	SUS	or	M	 7.73E-246	 0	 0.075	 0.120	 0.651	
1	 pncB1	 1499617	 PZA	 3.20E-06	 0	 0.003	 0.003	 0.004	
1	 echA12	 1660232	 X	v	SUS	 3.91E-24	 0	 0.003	 0.003	 0.004	
2	
Rv1482c-
fabG1	 1673425	 ETH	 1.91E-04	 0.003	 0.251	 0.115	 0.319	
1-4	
Rv1482c-
fabG1	 1673425	 M	or	X	v	SUS,	INH	 4.07E-56	 0.003	 0.251	 0.115	 0.319	
4	
Rv1482c-




Lineage	 Gene	 Position	 Drug	 Min	P-value	 Susc.	 DR	 MDR-TB	 XDR-TB	
4	 inhA	 1674481	 X	v	SUS	 8.54E-46	 0	 0.076	 0.010	 0.075	
1,4	 inhA	 1674782	 M	or	X	v	SUS	 3.91E-24	 0	 0.040	 0.019	 0.075	
1-4	 katG	 2155168	 M	or	X	v	SUS,	INH	 3.26E-286	 0.004	 0.424	 0.820	 0.795	
4	 pncA	 2288868	 X	v	SUS,	PZA	 1.60E-14	 0	 0.02	 0.018	 0.024	
1	 pncA	 2288952	 M	or	X	v	SUS,	PZA	 3.91E-24	 0	 0.009	 0.003	 0.004	
2	
pncA-
Rv2044c	 2289252	 PZA	 1.12E-08	 0	 0.008	 0.036	 0.016	
4	 eis-Rv2417c	 2715342	 KAN	 1.93E-08	 0	 0.025	 0.043	 0.056	
2	 oxyR'-ahpC	 2726141	 X	v	SUS	 4.53E-08	 0.001	 0.008	 0.022	 0.008	
2	 alr	 3841083	 Cycloserine	 1.67E-08	 0	 0.007	 0.008	 0.100	
2,4	 embC-embA	 4243217	 X	or	M	v	SUS,	EMB	 2.09E-14	 0	 0.026	 0.043	 0.079	
3,4	 embC-embA	 4243221	 X	v	SUS,	EMB	 1.70E-32	 0	 0.017	 0.043	 0.067	
4	 embC-embA	 4243222	 X	v	SUS,	EMB	 2.62E-10	 0	 0.013	 0.01	 0.036	
1-4	 embB	 4247429	 M	or	X	v	SUS,	EMB	 1.28E-47	 0.001	 0.109	 0.358	 0.399	
1-4	 embB	 4247431	 M	or	X	v	SUS,	EMB	 1.58E-51	 0.003	 0.071	 0.221	 0.375	
1	 embB	 4247574	 X	or	M	v	SUS,	EMB	 3.63E-07	 0	 0.007	 0.023	 0.016	
4	 embB	 4247702	 X	v	SUS,	EMB	 2.62E-08	 0	 0.013	 0.006	 0.028	
4	 embB	 4247729	 X	or	M	v	SUS,	EMB	 8.81E-13	 0	 0.008	 0.023	 0.012	
2,4	 embB	 4247730	 X	v	SUS,	EMB	 3.31E-12	 0	 0.025	 0.066	 0.043	
4	 embB	 4247781	 X	v	SUS	 9.20E-10	 0	 0.02	 0.007	 0.024	




Lineage	 Gene	 Position	 Drug	 Min	P-value	 Susc.	 DR	 MDR-TB	 XDR-TB	
3	 embB	 4249583	 X	v	SUS,	EMB	 5.84E-23	 0	 0.007	 0.015	 0.016	
4	 ubiA	 4269271	 X	v	M	or	SUS	 1.01E-16	 0	 0.001	 0.003	 0.185	
3	 ethA	 4326435	 X	v	SUS	 3.44E-14	 0	 0.001	 0	 0.016	
4	 ethA-ethR	 4327484	 X	v	SUS	 9.24E-44	 0	 0.007	 0.054	 0.192	
4	 ethR	 4328127	 X	v	SUS	 9.30E-10	 0	 0.020	 0.007	 0.024	





















Rifampicin	 rpoB	 rpoC*	 <	2.2e-16	
Rifampicin	 rpoB	 rpoA*	 6.0e-09	
Isoniazid	 katG	 ahpC*	 <	2.2e-16	
Pyrazinamide	 pncA	 pncB2	 1.4e-13	
Ethambutol	 embB	 ubiA	 <	2.2e-16	



























	 		 Overall	 Lineage	1	 Lineage	2	 Lineage	3	 Lineage	4	
		 		 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	
rpoC	
WT	 4964	 873	 557	 30	 417	 322	 888	 49	 3102	 472	
Mut.	 138	 477	 15	 15	 25	 251	 28	 28	 70	 183	
rpoA	
WT	 5060	 1308	 564	 45	 439	 553	 915	 76	 3142	 634	
Mut.	 43	 42	 8	 0	 3	 20	 1	 1	 31	 21	
	
	 		 katG	
	 		 Overall	 Lineage	1	 Lineage	2	 Lineage	3	 Lineage	4	
		 		 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	
ahpC	
promoter	
WT	 4959	 1390	 554	 58	 472	 525	 826	 156	 3107	 651	




	 		 Overall	 Lineage	1	 Lineage	2	 Lineage	3	 Lineage	4	
		 		 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	
pncB2	
WT	 5608	 599	 560	 23	 704	 280	 953	 18	 3391	 278	
Mut.	 116	 59	 24	 0	 9	 0	 13	 0	 70	 59	
pncB1	
WT	 5576	 647	 528	 15	 701	 280	 927	 17	 3420	 335	
Mut.	 147	 11	 58	 8	 12	 0	 37	 1	 40	 2	
	
	 		 ethA	
	 		 Overall	 Lineage	1	 Lineage	2	 Lineage	3	 Lineage	4	
		 		 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	
pyrG	
WT	 5922	 285	 541	 33	 914	 59	 933	 43	 3534	 150	
Mut.	 143	 15	 38	 1	 7	 2	 14	 0	 84	 12	
Rv0565c	
WT	 5969	 292	 562	 34	 914	 56	 915	 42	 3578	 160	









	 		 Overall	 Lineage	1	 Lineage	2	 Lineage	3	 Lineage	4	
		 		 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	
ubiA	
WT	 5033	 1281	 502	 91	 489	 475	 886	 97	 3156	 618	
Mut.	 45	 104	 21	 3	 3	 54	 9	 1	 12	 46	
	
	 		 thyA	
	 		 Overall	 Lineage	1	 Lineage	2	 Lineage	3	 Lineage	4	
		 		 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	 WT	 Mut.	
thyX-
hsdS1	
WT	 6332	 36	 600	 4	 982	 10	 973	 14	 3777	 8	


































3840259	 Y388D	 0.0009	 0	 -3.369	 -3.384	 -3.737	 2.682	 -2.819	
3840258	 Y388C	 0.0002	 0	 -1.889	 -1.704	 -1.938	 2.682	 -2.489	
3840393	 M343T_B	 0.0031	 0.0358	 -2.118	 -2.085	 0.368	 3.636	 -0.195	
3840708	 S238L	 0.0002	 0	 0.611	 1.192	 0.69	 4.246	 -0.551	
3840952	 K157E	 0.0003	 0	 -1.483	 -1.455	 -1.841	 4.474	 -0.075	
3840636	 P262Q	 0.0012	 0	 -2.015	 -2.069	 0.279	 4.987	 -0.863	
3840717	 S235W	 0.0002	 0	 -0.807	 -1.46	 0.706	 5.212	 -0.588	
3840402	 R340L_B	 0.0003	 0	 -0.57	 0.616	 0.16	 5.389	 -0.629	
3840643	 L260V	 0.0002	 0	 -1.244	 -1.554	 -2.467	 6.992	 -0.419	
3840639	 S261N	 0.0002	 0	 -1.443	 -1.606	 -0.482	 7.116	 -0.248	
3841083	 L113R	 0.0057	 0.4461	 -0.961	 -0.956	 -1.721	 8.477	 -0.423	
CYS	=	D-cycloscerine;	*	protein	stability;	**	drug	binding,	***	protein-protein	interactions;	bolded	the	mutation	that	was	statistically	
significant;	grey	–	less	stability		
We	applied	 four	measures	 to	quantify	 the	enthalpic	effects	 (the	 change	 in	Gibbs	 free	energy	 -	∆∆G)	of	point	mutations	on	overall	 protein	
structure	stability	(mCSM	and	DUET),	protein-protein	interactions	(mCSM-PPI)	and	interaction	with	substrate/drug	(mCSM-Lig).	Negative	values	





























MDR-TB	vs.	Susc.	 pncA	 44.72	 25	 1	 1-15	 3.83E-10	
MDR-TB	vs.	Susc.	 rpoB	 2.27	 7	 6	 3-9	 3.49E-06	
MDR-TB	vs.	Susc.	 embCAB	promoter	 72.29	 6	 1	 1-2	 1.71E-04	
XDR-TB	vs.	Susc.	 ethA	 25.89	 38	 1	 1-10	 4.25E-54	
XDR-TB	vs.	Susc.	 pncA	 44.72	 25	 1	 1-15	 5.51E-38	
XDR-TB	vs.	Susc.	 rpoB	 2.27	 7	 6	 3-9	 1.31E-12	
XDR-TB	vs.	Susc.	 embCAB	promoter	 72.29	 6	 1	 1-2	 1.29E-29	
XDR-	vs.	MDR-TB	 pncA	 44.72	 25	 1	 1-15	 1.50E-04	
XDR-	vs.	MDR-TB	 katG	 5.40	 12	 1.5	 1-12	 2.33E-02	
Isoniazid	 katG	 5.40	 12	 1.5	 1-12	 2.82E-05	
Rifampicin	 rpoB	 2.27	 7	 6	 3-9	 1.25E-10	
Ethionamide	 ethA	 25.89	 38	 1	 1-10	 7.22E-09	
Capreomycin	 tlyA	 3.73	 3	 2	 2-10	 1.21E-12	
Capreomycin	 rrs	 2.61	 4	 1	 1-1	 2.37E-10	
Streptomycin	 gid	 35.66	 24	 1	 1-14	 1.45E-09	
Pyrazinamide	 pncA	 44.72	 25	 1	 1-15	 5.27E-38	
Cycloserine	 ald	 10.77	 12	 1	 1-5	 5.35E-03	

















dfrA/thyA	 5	 PAS	 1	 3	 6,396	 2,825-7,912	
pncA	 12	 PZA	 1	 3	 1,402	 446-4,670	
ethA/ethR	 7	 ETH	 3	 3	 3,667	 1,513-5,271	
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M.	aurum	 and	 the	mycobacterium	phylogeny	 constructed	using	16S	 rRNA	 sequences,	



















































































































































katG1	(2277bp)	 Yes	 Yes	 Yes	
737bp	from	start	codon	
729	bp	from	stop	codon	
katG2	(2235bp)	 Yes	 Yes	 Yes	
821bp	from	start	codon	
embB1	(3276bp)	 Yes	 Yes	 No		
















































published?	 	 	 	 	 	 	
Please	list	the	paper’s	authors	in	the	





























Student	Signature:		 	 	 	 	 	 	 Date:		 	 	 	
	
	

























































Brazil	 42	 -	 -	 -	 42	
Bulgaria	 2	 -	 -	 -	 2	
China	 6	 -	 -	 5	 1	
Malawi	 257	 38	 8	 28	 183	
Netherlands	 10	 -	 -	 -	 10	
Pakistan	 31	 4	 4	 19	 4	
Peru	 65	 -	 5	 -	 60	
Portugal	 78	 -	 5	 -	 73	
South	Africa	 27	 -	 16	 1	 10	
























































1	 42	(8.1)	 187.7	 127.7	 0.00009	 0.00017	 36	
2	 38	(7.3)	 319.7	 151.1	 0.00002	 0.00007	 15	
3	 53	(10.2)	 329.5	 174.0	 0.00004	 0.00007	 28	
4	 385	(74.3)	 268.3	 150.9	 0.00007	 0.00016	 8	





















Rv0109	 pe_pgrs1	 1490	 0	(0)	 0.99	 23	 13	
Rv0124	 pe_pgrs2	 1463	 0	(0)	 0.93	 27	 18	
Rv0151c	 pe1	 1766	 0	(0)	 0.99	 32	 20	
Rv0152c	 pe2	 1577	 0	(0)	 1	 21	 15	
Rv0159c	 pe3	 1406	 0	(0)	 1	 18	 13	
Rv0160c	 pe4	 1508	 0	(0)	 1	 16	 10	
Rv0278c	 pe_pgrs3	 2873	 0	(0)	 0.78	 281	 135	
Rv0279c	 pe_pgrs4	 2513	 241	(0.1)	 0.25	 110	 52	
Rv0285	 pe5	 308	 0	(0)	 1	 4	 2	
Rv0297	 pe_pgrs5	 1775	 0	(0)	 0.98	 23	 16	
Rv0335c	 pe6	 515	 0	(0)	 1	 28	 17	
Rv0532	 pe_pgrs6	 1784	 0	(0)	 0.95	 69	 46	
Rv0578c	 pe_pgrs7	 3920	 0	(0)	 0.75	 120	 55	
Rv0742	 pe_pgrs8	 527	 0	(0)	 0.99	 3	 2	
Rv0746	 pe_pgrs9	 2351	 23	(0.01)	 0.44	 68	 41	
Rv0747	 pe_pgrs10	 2405	 0	(0)	 0.56	 188	 100	
Rv0754	 pe_pgrs11	 1754	 0	(0)	 1	 13	 8	
Rv0832	 pe_pgrs12	 413	 0	(0)	 1	 2	 2	
Rv0833	 pe_pgrs13	 2249	 0	(0)	 0.77	 63	 42	
Rv0834c	 pe_pgrs14	 2648	 0	(0)	 0.92	 62	 26	
Rv0872c	 pe_pgrs15	 1820	 0	(0)	 1	 16	 9	
Rv0916c	 pe7	 299	 0	(0)	 1	 3	 3	
Rv0977	 pe_pgrs16	 2771	 0	(0)	 0.82	 136	 103	
Rv0978c	 pe_pgrs17	 995	 0	(0)	 0.51	 33	 19	
Rv0980c	 pe_pgrs18	 1373	 318	(0.23)	 0.14	 48	 26	
Rv1040c	 pe8	 827	 0	(0)	 1	 4	 3	
Rv1067c	 pe_pgrs19	 2003	 305.5	(0.15)	 0.12	 81	 40	
Rv1068c	 pe_pgrs20	 1391	 207	(0.15)	 0.2	 5	 5	
Rv1087	 pe_pgrs21	 2303	 0	(0)	 0.58	 77	 48	
Rv1088	 pe9	 434	 0	(0)	 1	 3	 2	
Rv1089	 pe10	 362	 0	(0)	 1	 5	 4	
Rv1091	 pe_pgrs22	 2561	 197	(0.08)	 0.13	 55	 28	
Rv1172c	 pe12	 926	 0	(0)	 1	 6	 3	
Rv1195	 pe13	 299	 0	(0)	 1	 12	 9	
Rv1214c	 pe14	 332	 0	(0)	 1	 4	 2	
Rv1243c	 pe_pgrs23	 1688	 0	(0)	 0.91	 11	 8	
 224 
Rv1325c	 pe_pgrs24	 1811	 0	(0)	 0.88	 54	 23	
Rv1386	 pe15	 308	 0	(0)	 1	 3	 2	
Rv1396c	 pe_pgrs25	 1730	 0	(0)	 0.96	 36	 20	
Rv1430	 pe16	 1586	 0	(0)	 1	 12	 10	
Rv1441c	 pe_pgrs26	 1475	 0	(0)	 0.85	 14	 10	
Rv1450c	 pe_pgrs27	 3989	 418	(0.1)	 0.3	 55	 29	
Rv1452c	 pe_pgrs28	 2225	 22	(0.01)	 0.49	 51	 19	
Rv1468c	 pe_pgrs29	 1112	 0	(0)	 1	 16	 7	
Rv1646	 pe17	 932	 0	(0)	 1	 2	 2	
Rv1651c	 pe_pgrs30	 3035	 0	(0)	 0.98	 40	 20	
Rv1768	 pe_pgrs31	 1856	 0	(0)	 0.97	 22	 17	
Rv1788	 pe18	 299	 0	(0)	 0.95	 15	 14	
Rv1791	 pe19	 299	 0	(0)	 0.99	 17	 13	
Rv1803c	 pe_pgrs32	 1919	 0	(0)	 1	 27	 17	
Rv1806	 pe20	 299	 0	(0)	 1	 3	 2	
Rv1818c	 pe_pgrs33	 1496	 0	(0)	 0.98	 36	 14	
Rv1840c	 pe_pgrs34	 1547	 0	(0)	 0.99	 22	 13	
Rv1983	 pe_pgrs35	 1676	 0	(0)	 1	 14	 9	
Rv2098c	 pe_pgrs36	 1304	 0	(0)	 0.99	 7	 5	
Rv2099c	 pe21	 173	 0	(0)	 1	 3	 2	
Rv2107	 pe22	 296	 0	(0)	 1	 2	 1	
Rv2126c	 pe_pgrs37	 770	 0	(0)	 0.99	 21	 12	
Rv2162c	 pe_pgrs38	 1598	 0	(0)	 0.79	 45	 16	
Rv2328	 pe23	 1148	 0	(0)	 1	 9	 7	
Rv2340c	 pe_pgrs39	 1241	 0	(0)	 1	 16	 9	
Rv2371	 pe_pgrs40	 185	 0	(0)	 1	 1	 0	
Rv2396	 pe_pgrs41	 1085	 0	(0)	 0.91	 26	 15	
Rv2408	 pe24	 719	 0	(0)	 1	 5	 4	
Rv2431c	 pe25	 299	 0	(0)	 1	 3	 2	
Rv2487c	 pe_pgrs42	 2084	 0	(0)	 0.85	 21	 10	
Rv2490c	 pe_pgrs43	 4982	 14	(0)	 0.43	 103	 44	
Rv2519	 pe26	 1478	 0	(0)	 1	 19	 11	
Rv2591	 pe_pgrs44	 1631	 0	(0)	 0.96	 19	 12	
Rv2615c	 pe_pgrs45	 1385	 0	(0)	 0.51	 27	 11	
Rv2634c	 pe_pgrs46	 2336	 0	(0)	 0.97	 21	 10	
Rv2741	 pe_pgrs47	 1577	 0	(0)	 0.86	 56	 33	
Rv2769c	 pe27	 827	 0	(0)	 1	 13	 11	
Rv2853	 pe_pgrs48	 1847	 0	(0)	 0.98	 24	 17	
Rv3018A	 pe27A	 86	 0	(0)	 0.69	 0	 0	
Rv3022A	 pe29	 314	 0	(0)	 0.98	 0	 0	
Rv3344c	 pe_pgrs49	 1454	 0	(0)	 0.78	 47	 16	
Rv3345c	 pe_pgrs50	 4616	 125	(0.03)	 0.22	 207	 105	
Rv3367	 pe_pgrs51	 1766	 0	(0)	 1	 15	 7	
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Rv3388	 pe_pgrs52	 2195	 0	(0)	 0.76	 48	 33	
Rv3477	 pe31	 296	 0	(0)	 1	 10	 8	
Rv3507	 pe_pgrs53	 4145	 0	(0)	 0.64	 133	 97	
Rv3508	 pe_pgrs54	 5705	 2018	(0.35)	 0	 358	 200	
Rv3511	 pe_pgrs55	 2144	 233	(0.11)	 0.2	 119	 74	
Rv3512	 pe_pgrs56	 3239	 345	(0.11)	 0.04	 174	 114	
Rv3514	 pe_pgrs57	 4469	 2651	(0.59)	 0	 39	 29	
Rv3590c	 pe_pgrs58	 1754	 8	(0)	 0.48	 49	 17	
Rv3595c	 pe_pgrs59	 1319	 0	(0)	 1	 22	 8	
Rv3622c	 pe32	 299	 0	(0)	 0.99	 3	 2	
Rv3650	 pe33	 284	 0	(0)	 1	 4	 3	
Rv3652	 pe_pgrs60	 314	 0	(0)	 1	 7	 4	
Rv3653	 pe_pgrs61	 587	 0	(0)	 0.99	 10	 8	
Rv3746c	 pe34	 335	 0	(0)	 1	 8	 8	
Rv3812	 pe_pgrs62	 1514	 0	(0)	 1	 20	 14	
Rv3872	 pe35	 299	 0	(0)	 1	 3	 3	
Rv3893c	 pe36	 233	 0	(0)	 1	 1	 1	
Rv0096	 ppe1	 1391	 0	(0)	 1	 27	 19	
Rv0256c	 ppe2	 1670	 0	(0)	 1	 17	 9	
Rv0280	 ppe3	 1610	 0	(0)	 1	 18	 12	
Rv0286	 ppe4	 1541	 0	(0)	 1	 16	 11	
Rv0304c	 ppe5	 6614	 0	(0)	 0.97	 65	 37	
Rv0305c	 ppe6	 2891	 0	(0)	 1	 36	 22	
Rv0354c	 ppe7	 425	 0	(0)	 1	 4	 3	
Rv0355c	 ppe8	 9902	 12	(0)	 0.46	 329	 189	
Rv0388c	 ppe9	 542	 0	(0)	 1	 11	 2	
Rv0442c	 ppe10	 1463	 0	(0)	 0.98	 14	 9	
Rv0453	 ppe11	 1556	 0	(0)	 1	 18	 12	
Rv0755c	 ppe12	 1937	 0	(0)	 1	 20	 11	
Rv0878c	 ppe13	 1331	 0	(0)	 1	 13	 8	
Rv0915c	 ppe14	 1271	 0	(0)	 1	 12	 8	
Rv1039c	 ppe15	 1175	 0	(0)	 1	 9	 7	
Rv1135c	 ppe16	 1856	 0	(0)	 1	 22	 18	
Rv1168c	 ppe17	 1040	 0	(0)	 1	 9	 7	
Rv1196	 ppe18	 1175	 0	(0)	 0.56	 6	 2	
Rv1361c	 ppe19	 1190	 0	(0)	 0.7	 53	 31	
Rv1387	 ppe20	 1619	 0	(0)	 1	 16	 11	
Rv1548c	 ppe21	 2036	 0	(0)	 0.99	 24	 19	
Rv1705c	 ppe22	 1157	 0	(0)	 0.99	 20	 13	
Rv1706c	 ppe23	 1184	 0	(0)	 0.99	 10	 4	
Rv1753c	 ppe24	 3161	 282	(0.09)	 0	 68	 35	
Rv1787	 ppe25	 1097	 375	(0.34)	 0.36	 6	 5	
Rv1789	 ppe26	 1181	 0	(0)	 0.94	 13	 8	
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Rv1790	 ppe27	 1052	 0	(0)	 0.53	 12	 10	
Rv1800	 ppe28	 1967	 0	(0)	 1	 33	 27	
Rv1801	 ppe29	 1271	 0	(0)	 0.99	 9	 4	
Rv1802	 ppe30	 1391	 0	(0)	 1	 25	 17	
Rv1807	 ppe31	 1199	 0	(0)	 1	 12	 6	
Rv1808	 ppe32	 1229	 0	(0)	 1	 13	 5	
Rv1809	 ppe33	 1406	 0	(0)	 1	 14	 9	
Rv1917c	 ppe34	 4379	 348	(0.08)	 0	 132	 63	
Rv1918c	 ppe35	 2963	 0	(0)	 0.98	 54	 34	
Rv2108	 ppe36	 731	 0	(0)	 1	 10	 7	
Rv2123	 ppe37	 1421	 0	(0)	 0.99	 20	 14	
Rv2352c	 ppe38	 1175	 0	(0)	 0.92	 37	 15	
Rv2353c	 ppe39	 1064	 0	(0)	 0.56	 73	 40	
Rv2356c	 ppe40	 1847	 0	(0)	 0.95	 23	 11	
Rv2430c	 ppe41	 584	 0	(0)	 0.92	 6	 3	
Rv2608	 ppe42	 1742	 0	(0)	 1	 11	 5	
Rv2768c	 ppe43	 1184	 0	(0)	 1	 17	 12	
Rv2770c	 ppe44	 1148	 0	(0)	 1	 14	 10	
Rv2892c	 ppe45	 1226	 0	(0)	 0.99	 10	 7	
Rv3018c	 ppe46	 1304	 151.5	(0.12)	 0.45	 22	 12	
Rv3021c	 ppe47	 1076	 223.5	(0.21)	 0.09	 4	 1	
Rv3022c	 ppe48	 242	 133.5	(0.55)	 0.36	 1	 0	
Rv3125c	 ppe49	 1175	 0	(0)	 0.98	 26	 17	
Rv3135	 ppe50	 398	 0	(0)	 0.68	 0	 0	
Rv3136	 ppe51	 1142	 0	(0)	 1	 17	 10	
Rv3144c	 ppe52	 1229	 0	(0)	 1	 10	 6	
Rv3159c	 ppe53	 1772	 0	(0)	 0.99	 24	 13	
Rv3343c	 ppe54	 7571	 543.5	(0.07)	 0.06	 163	 80	
Rv3347c	 ppe55	 9473	 0	(0)	 0.55	 0	 0	
Rv3350c	 ppe56	 11150	 0	(0)	 0.54	 0	 0	
Rv3425	 ppe57	 530	 2	(0)	 0.46	 37	 35	
Rv3426	 ppe58	 698	 697	(1)	 0.49	 0	 0	
Rv3429	 ppe59	 536	 0	(0)	 0.89	 86	 73	
Rv3478	 ppe60	 1181	 0	(0)	 0.92	 155	 110	
Rv3532	 ppe61	 1220	 0	(0)	 1	 11	 9	
Rv3533c	 ppe62	 1748	 0	(0)	 0.99	 16	 6	
Rv3539	 ppe63	 1439	 0	(0)	 1	 13	 9	
Rv3558	 ppe64	 1658	 0	(0)	 1	 17	 14	
Rv3621c	 ppe65	 1241	 0	(0)	 1	 19	 14	
Rv3738c	 ppe66	 947	 0	(0)	 0.9	 0	 0	
Rv3739c	 ppe67	 233	 0	(0)	 0.9	 2	 1	
Rv3873	 ppe68	 1106	 0	(0)	 1	 13	 7	
Rv3892c	 ppe69	 1199	 0	(0)	 1	 12	 6	
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Rv1169c	 pe11		 302	 0	(0)	 1	 2	 2	
Rv3020c	 pe28	 293	 0	(0)	 0.73	 0	 0	





























Position	 Mutation	 Locus	Tag	 Gene	 NS/S	 Lineage	
132646	 G/T	 Rv0109	 pe_pgrs1	 NS	 1	
189948	 C/G	 Rv0160c	 pe4	 S	 1	
308312	 G/A	 Rv0256c	 ppe2	 S	 1	
339508	 C/T	 Rv0280	 ppe3	 S	 1	
362007	 G/A	 Rv0297	 pe_pgrs5	 NS	 1	
368948	 T/C	 Rv0304c	 ppe5	 NS	 1	
372149	 G/A	 Rv0304c	 ppe5	 NS	 1	
426768	 C/T	 Rv0355c	 ppe8	 NS	 1	
434327	 A/G	 Rv0355c	 ppe8	 NS	 1	
673066	 C/G	 Rv0578c	 pe_	pgrs7	 S	 1	
673344	 A/T	 Rv0578c	 pe_	pgrs7	 S	 1	
846996	 G/A	 Rv0754	 pe_	pgrs11	 NS	 1	
928483	 C/T	 Rv0834c	 pe_pgrs14	 NS	 1	
977196	 G/A	 Rv0878c	 ppe13	 S	 1	
1188917	 G/A	 Rv1067c	 pe_pgrs19	 NS	 1	
1656178	 C/T	 Rv1468c	 pe_pgrs29	 NS	 1	
1863660	 C/T	 Rv1651c	 pe_pgrs30	 NS	 1	
2045849	 C/T	 Rv1803c	 pe_pgrs32	 NS	 1	
2165256	 T/G	 Rv1917c	 ppe34	 NS	 1	
2423785	 C/T	 Rv2162c	 pe_pgrs38	 NS	 1	
2803867	 G/C	 Rv2490c	 pe_	pgrs43	 S	 1	
2961099	 G/A	 Rv2634c	 pe_	pgrs46	 NS	 1	
3053973	 C/T	 Rv2741	 pe_	pgrs47	 S	 1	
3080282	 C/A	 Rv2770c	 ppe44	 NS	 1	
3929996	 G/T	 Rv3507	 pe_pgrs53	 NS	 1	
3936696	 A/G	 Rv3508	 pe_pgrs54	 NS	 1	
3942239	 C/A	 Rv3512	 pe_pgrs56	 S	 1	
3944807	 T/C	 Rv3512	 pe_pgrs56	 S	 1	
3970112	 C/T	 Rv3532	 ppe61	 NS	 1	
3979151	 T/A	 Rv3539	 ppe63	 NS	 1	
3998895	 G/A	 Rv3558	 ppe64	 NS	 1	
4061113	 G/T	 Rv3621c	 ppe65	 S	 1	
4093719	 G/A	 Rv3652	 pe_pgrs60	 NS	 1	
4277032	 G/C	 Rv3812	 pe_pgrs62	 NS	 1	
4351759	 G/C	 Rv3873	 ppe68	 NS	 1	
4375318	 G/A	 Rv3892c	 ppe69	 NS	 1	
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424981	 G/A	 Rv0355c	 ppe8	 S	 2	
1212432	 C/A	 Rv1087	 pe_pgrs21	 S	 2	
1217065	 C/A	 Rv1091	 pe_pgrs22	 S	 2	
1217157	 A/C	 Rv1091	 pe_pgrs22	 NS	 2	
1218658	 G/C	 Rv1091	 pe_pgrs22	 S	 2	
1299305	 G/A	 Rv1168c	 ppe17	 NS	 2	
1357308	 T/G	 Rv1214c	 pe14	 S	 2	
1606673	 G/T	 Rv1430	 pe16	 S	 2	
2601760	 G/A	 Rv2328	 pe23	 NS	 2	
2706663	 G/T	 Rv2408	 pe24	 NS	 2	
2922846	 C/T	 Rv2591	 pe_pgrs44	 S	 2	
2922848	 A/T	 Rv2591	 pe_pgrs44	 NS	 2	
3895585	 C/T	 Rv3478	 ppe60	 NS	 2	
4032218	 G/A	 Rv3590c	 pe_pgrs58	 NS	 2	
4032625	 G/T	 Rv3590c	 pe_pgrs58	 S	 2	
178205	 C/G	 Rv0151c	 pe1	 S	 3	
178453	 C/G	 Rv0151c	 pe1	 S	 3	
188317	 A/G	 Rv0159c	 pe3	 NS	 3	
189850	 A/G	 Rv0160c	 pe4	 NS	 3	
308661	 A/G	 Rv0256c	 ppe2	 NS	 3	
350088	 C/A	 Rv0286	 ppe4	 NS	 3	
367718	 G/T	 Rv0304c	 ppe5	 NS	 3	
369886	 C/G	 Rv0304c	 ppe5	 S	 3	
428921	 G/A	 Rv0355c	 ppe8	 NS	 3	
432459	 C/T	 Rv0355c	 ppe8	 NS	 3	
531775	 C/G	 Rv0442c	 ppe10	 S	 3	
623163	 C/T	 Rv0532	 pe_pgrs6	 NS	 3	
674702	 A/T	 Rv0578c	 pe_pgrs7	 S	 3	
840847	 C/T	 Rv0747	 pe_pgrs10	 S	 3	
1488428	 C/T	 Rv1325c	 pe_pgrs24	 NS	 3	
1489142	 C/T	 Rv1325c	 pe_pgrs24	 NS	 3	
1856617	 C/T	 Rv1646	 pe17	 NS	 3	
1863584	 G/T	 Rv1651c	 pe_pgrs30	 NS	 3	
2051345	 G/A	 Rv1809	 ppe33	 NS	 3	
2382289	 G/T	 Rv2123	 ppe37	 NS	 3	
2836773	 C/T	 Rv2519	 pe26	 NS	 3	
2943675	 G/A	 Rv2615c	 pe_pgrs45	 S	 3	
2960592	 C/T	 Rv2634c	 pe_pgrs46	 NS	 3	
3738364	 G/A	 Rv3344c	 ppe52	 NS	 3	
3738364	 G/A	 Rv3345c	 pe_pgrs50	 S	 3	
3740181	 T/C	 Rv3345c	 pe_pgrs50	 NS	 3	
3741240	 C/T	 Rv3345c	 pe_pgrs50	 NS	 3	
4375452	 G/A	 Rv3892c	 ppe69	 NS	 3	
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428698	 T/C	 Rv0355c	 ppe8	 S	 4	
1618978	 C/T	 Rv1441c	 pe_pgrs26	 NS	 4	
1931718	 C/G	 Rv1705c	 ppe22	 S	 4	
2050822	 C/G	 Rv1808	 ppe32	 NS	 4	
2167926	 G/A	 Rv1918c	 ppe35	 NS	 4	
3079877	 G/A	 Rv2770c	 ppe44	 NS	 4	
3466919	 G/C	 Rv3097c	 lipY	 S	 4	








































Name	 Locus	 Length	 Function	 No.	sites	
pe_pgrs3	 Rv0278c	 2873	 pe/ppe	 49	
pe_pgrs54	 Rv3508	 5705	 pe/ppe	 39	
Rv0668	 Rv0668	 3950	 information	pathways	 34	
pe_pgrs57	 Rv3514	 4469	 pe/ppe	 33	
ppe54	 Rv3343c	 7571	 pe/ppe	 32	
pe_pgrs56	 Rv3512	 3239	 pe/ppe	 29	
ppe55	 Rv3347c	 9473	 pe/ppe	 29	
ppe56	 Rv3350c	 11150	 pe/ppe	 26	
pks12	 Rv2048c	 12455	 lipid	metabolism	 25	
pe_pgrs28	 Rv1452c	 2225	 pe/ppe	 23	
Rv2850c	 Rv2850c	 1889	 metabolism	&	respiration	 21	
Rv0075	 Rv0075	 1172	 metabolism	&	respiration	 20	
lppA	 Rv2543	 659	 cell	wall	&	cell	processes	 20	
lppB	 Rv2544	 662	 cell	wall	&	cell	processes	 19	
pe_pgrs50	 Rv3345c	 4616	 pe/ppe	 18	
ppe57	 Rv3425	 530	 pe/ppe	 18	
Rv1453	 Rv1453	 1265	 regulatory	proteins	 18	
ppsA	 Rv2931	 5630	 lipid	metabolism	 18	
Rv1722	 Rv1722	 1484	 lipid	metabolism	 17	
ctpJ	 Rv3743c	 1982	 cell	wall	&	cell	processes	 17	
pe_pgrs17	 Rv0978c	 995	 pe/ppe	 16	
pe_pgrs18	 Rv0980c	 1373	 pe/ppe	 16	
fadE1	 Rv0131c	 1343	 lipid	metabolism	 16	
Rv1729c	 Rv1729c	 938	 lipid	metabolism	 16	
pe_pgrs19	 Rv1067c	 2003	 pe/ppe	 15	
pe_pgrs4	 Rv0279c	 2513	 pe/ppe	 15	
pe_pgrs16	 Rv0977	 2771	 pe/ppe	 14	
Rv2978c	 Rv2978c	 1379	 insertion	sequences	&	phages	 14	
pe_pgrs21	 Rv1087	 2303	 pe/ppe	 13	
pe_pgrs9	 Rv0746	 2351	 pe/ppe	 13	
ppe8	 Rv0355c	 9902	 pe/ppe	 13	
Rv0080	 Rv0080	 458	 NA	 13	
treY	 Rv1563c	 2297	 virulence,	detoxification	&	adaptation	 13	
Rv2827c	 Rv2827c	 887	 NA	 13	
Rv2082	 Rv2082	 2165	 NA	 12	
pe_pgrs10	 Rv0747	 2405	 pe/ppe	 11	
ppe10	 Rv0442c	 1463	 pe/ppe	 11	
Rv0893c	 Rv0893c	 977	 lipid	metabolism	 11	
Rv1254	 Rv1254	 1151	 metabolism	&	respiration	 11	
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Rv1776c	 Rv1776c	 560	 regulatory	proteins	 11	









































































































































































































































Allele	 frequency	 spectra	 for	 each	 lineage	 by	 synonymous	 (blue)	 and	 non-synonymous	
(red)	mutations.	The	peaks	at	intermediate	allele	frequencies	include	sub-lineage	defining	












































Site	 wise	 log	 likelihood	 score	 (Δ	 SSLS)	 is	 calculated	 for	 each	 SNP	 in	 the	 pe/ppe	 gene	
alignments.	Negative	differences	indicate	SNP	positions	favouring	the	pe/ppe	tree.	SNPs	































to	be	recombination	hotspots	 in	each	 lineage	 (Lineage	1	 Indo-Oceanic;	Lineage	2	East-
Asian	(Beijing);	Lineage	3	East-African-Indian;	Lineage	4	Euro-American).	The	(−log10)	p-
































Selection	 dN/dS	 values	 for	 each	 gene	 within	 Clusters	 of	 Orthologous	 Groups	 (COG*)	
categories.	 *ppe/N = pe/ppe	 genes	 annotated	 as	 COG	 category	 N,	 *	 COG	
categories:	 A	 RNA	 processing	 and	 modification,	 B	 Chromatin	 Structure	 and	
dynamics,	C	Energy	production	and	conversion,	D	Cell	cycle	control	and	mitosis,	E	Amino	
Acid	metabolism	and	transport,	F	Nucleotide	metabolism	and	transport,	G	Carbohydrate	
metabolism	 and	 transport,	 H	 Coenzyme	 metabolism,	 ILipid	
metabolism,	 J	 Translation,	 K	 Transcription,	 L	 Replication	 and	 repair,	 M	 Cell	
wall/membrane/envelope	biogenesis,	N	Cell	motility,	O	Post-translational	modification,	
protein	 turnover,	 chaperone	 functions,	 P	 Inorganic	 ion	 transport	 and	
metabolism,	Q	Secondary	Structure,	T	Signal	Transduction,	U	Intracellular	trafficking	and	


















Non-neutral	 evolution	 for	 genes	 within	 Clusters	 of	 Orthologous	 Groups	 (COG*)	
categories.	Boxplots	are	constructed	using	(-log10)	p-values	of	non-neutral	evolution	for	
each	 gene.	 *ppe/N = pe/ppe	 genes	 annotated	 as	 COG	 category	 N,	 *	 COG	
categories:	 A	 RNA	 processing	 and	 modification,	 B	 Chromatin	 Structure	 and	
dynamics,	C	Energy	production	and	conversion,	D	Cell	cycle	control	and	mitosis,	E	Amino	
Acid	metabolism	and	transport,	F	Nucleotide	metabolism	and	transport,	G	Carbohydrate	
metabolism	 and	 transport,	 H	 Coenzyme	 metabolism,	 I	 Lipid	
metabolism,	 J	 Translation,	 KTranscription,	 L	 Replication	 and	 repair,	 M	 Cell	
wall/membrane/envelope	biogenesis,	N	Cell	motility,	O	Post-translational	modification,	
protein	 turnover,	 chaperone	 functions,	 P	 Inorganic	 ion	 transport	 and	
metabolism,	Q	Secondary	Structure,	TSignal	Transduction,	U	Intracellular	trafficking	and	
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cellular	processes,	 including	 transcription	and	chromosome	stability.	Advances	 in	PacBio	
sequencing	technologies	can	be	used	to	robustly	reveal	methylation	sites.	The	methylome	
of	the	Mycobacterium	tuberculosis	complex	is	poorly	understood	but	may	be	involved	in	

















new	 effective	 treatments	 and	 vaccines,	 are	 a	 major	 barrier	 to	 disease	 control.	 The	M.	
tuberculosis	 genome	 (size	 4.4Mb,	 GC-content	 60%)	 is	 characterised	 by	 low	 sequence	
diversity2,		with	known	variation	between	stain-types,	including	between	three	‘ancient’	(1,	
5,	 6),	 three	 ‘modern’	 (2,	 3,	 4),	 and	 one	 intermediate	 lineage	 (7)3.	 The	 lineages	 vary	 in	
propensity	to	transmit	and	cause	disease4;	with	modern	strain	lineages,	 including	Beijing	
strains,	 being	more	 successful	 in	 terms	of	 their	 geographical	 spread	and	have	a	 shorter	
latency	in	humans5.	However,	results	are	inconsistent	and	there	is	considerable	inter-strain	








host	 microenvironments7.	 Genetic	 and	 potentially	 transcriptomic	 differences,	 may	 play	
important	roles	 in	determining	the	clinical	outcome	differences	observed	between	these	
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lineage	 3	 strain	 and	 a	 H37Rv	 strain	 (CHIN_F1)	 from	 earlier	 work	 (n=2)8.	 High	 quality	
assemblies	 (no.	 contigs	 <10)	 were	 generated	 for	 the	 18	 isolates,	 with	 most	 isolates	
assembled	into	one	contig	(median	n50	=	4.38Mb,	median	genome	length	=	4.42Mb).	After	
aligning	to	the	H37Rv	reference,	we	found	10,353	unique	small	variant	sites,	with	50.7%	of	
positions	 having	 alternate	 alleles	 in	 only	 one	 sample.	 A	 maximum	 likelihood	 tree	 was	
constructed	 using	 the	 variants	 (Figure	 1)	 and	 demonstrated	 the	 expected	 clustering	 by	
lineage,	 with	 two	 lineage	 1	 strains	 (WBB1008_SL1975,	 WBB1007_LQ1975)	 being	 near	
identical.	
	















hypothesised	 from	 de	 novo	 assembly	 analysis	 to	 have	 undergone	 a	 large	 genomic	
rearrangement	in	Beijing	strains10.	The	PacBio	consensus	sequence	confirmed	the	large	re-
arrangements	in	WBB445_ARS7496	(Beijing).	These	re-arrangements	could	be	identified	in	




Annotation	 of	 the	 new	 reference	 genomes	 using	 prokka	 software11,	 guided	 by	 H37Rv	
protein	sequences,	revealed	differences	in	the	number	of	genes	(range:	4028	to	4217).	The	















isolates:	CACGCAG	 (17/18	 isolates),	GATN4RTAC	 (14/18),	and	CTCCAG	 (15/18)	 (Table	1).	
Partner	motifs	for	GATN4RTAC	and	CTCCAG	were	also	found	indicating	methylation	on	both	
the	 forward	 and	 reverse	 strand,	while	CACGCAG	 is	 only	hemi-methylated	 as	no	partner	
motif	 was	 found.	 These	 motifs	 have	 previously	 been	 reported8,12.	 The	 number	 of	




inter-pulse	duration	 (IPD)	 ratios	at	each	nucleotide	position	 in	 the	motif,	we	 found	 that	
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isolates	 where	 the	 motif	 was	 present	 but	 had	 no	 evidence	 of	 modification	 across	
nucleotides	(Supplementary	figure	3).	There	was	some	variability	across	and	within	strain	
types	in	the	percent	of	motifs	methylated.	In	particular,	although	motifs	were	mostly	close	
to	 100%	 (or	 alternatively	 0%)	 methylated,	 three	 isolates	 had	 a	 substantially	 different	
percentage	 for	 the	 CACGCAG	 motif	 (median	 (range)	 %:	 60.0	 (52.5-63.7))	 (Table	 2).	
Methylation	 of	 the	 other	 two	motifs	 (GATN4RTAC,	 CACGCAG)	 did	 not	 seem	 affected	 in	
these	isolates	(range	93.9	-	99.3%).		
	




of	 PacBio	 data,	 which	 could	 putatively	 explain	 loss	 of	 function	 in	 the	 respective	
methyltransferase.	 For	 the	GATN4RTAC	motif	we	 found	 three	 unique	mutations	 in	 four	
isolates	with	an	absence	of	methylation,	confirming	those	identified	in	previous	reports8.	




samples.	 One	 isolate	 had	 an	 E270A	mutation	 and	 frameshift	 deletion	 at	 position	 1257,	
however	 through	 phylogenetic	 ancestral	 reconstruction	 we	 deduced	 that	 the	 E270A	
mutation	occurred	before	the	deletion	(Figure	1).	The	two	other	 isolates	had	E270A	and	
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previously	 uncharacterised	 A460T	mutations,	 respectively.	 For	 the	 CACGCAG	motif,	 the	





To	 look	 for	 the	 non-random	 association	 of	 methylation	 sites	 and	 protein	 families	 or	
biological	pathways	we	performed	a	pathway	analysis	using	DAVID	software13.	Each	of	the	
three	 motifs	 was	 considered	 individually.	 Motifs	 were	 associated	 with	 genes	 based	 on	
overlap	with	an	annotated	coding	region	or	the	closest	promoter.	Most	motifs	were	found	
in	 the	 coding	 regions,	with	 few	 found	within	 promoters	 (defined	 as	 the	 50	 nucleotides	
before	a	start	codon)	(Supplementary	Figure	4).	For	GATN4RTAC,	we	found	an	enrichment	
of	cell	membrane	associated	genes	(Bonferroni	corrected	P-value	(P*)	=	0.021)	and	plasma	
associated	genes	 (P*	=	0.023)	 in	motif-containing	genes	compared	to	genes	without	 the	
motifs.	 	For	CTCCAG,	motif-containing	genes	were	enriched	 for	nucleotide	binding	 (P*	=	





genes	 to	 look	 for	 enrichment	 of	 specific	 pathways.	 This	 analysis	 was	 performed	 on	 an	
overall	 and	per-lineage	basis.	No	pathways	 reported	 significant	 results	 (P*>0.05).	When	
 259 
comparing	 motif-containing	 unmethylated	 to	 motif-containing	 methylated	 genes	 on	 a	



























genetic	 backgrounds.	 The	 ability	 of	 PacBio	 technology	 to	 produce	 long	 reads	 leads	 to	
complete	 genome	assemblies	 that	 capture	both	 small	 and	 large	 genomic	 variations	 and	
have	 a	 very	 high	 accuracy	 at	 repetitive	 regions	 such	 as	 the	 pe/ppe	 genes.	Most	 whole	
genome	sequencing	projects	have	focused	on	lineages	1	to	4	because	of	their	prevalence	
and	 global	 distribution,	 however	 recent	 studies	 have	 shown	 a	 large	 amount	 of	 genetic	
diversity	 to	 be	 present	 within	 lineages	 5	 and	 614.	 Additionally,	 an	 intriguing	 question	
remains	why	lineages	5	and	6	are	localised	to	West	Africa	and	have	not	spread	globally.	The	
lineage	 specific	 variants	 and	 differences	 in	 gene	 content	 (including	 the	 pe/ppe	 genes)	
reported	 here,	 building	 on	 previous	work3,	 could	 potentially	 play	 a	 role	 in	 specific	 host	









report	 a	 significant	 difference	 in	 the	 gene	 content	 between	 strains.	 Overall,	 these	 new	
reference	sequences	could	serve	to	improve	the	accuracy	of	resequencing	experiments	by	
facilitating	 lineage-specific	 mapping	 at	 highly	 variable	 regions	 and	 to	 improve	 our	
understanding	 of	 large	 structural	 variations	 such	 as	 novel	 insertions,	 as	 well	 as	
rearrangements	between	lineages.		
	




on	 both	 other	 motifs.	 We	 identified	 a	 number	 of	 mutations	 which	 associate	 with	 the	












reported	 to	be	highly	 virulent15,	 lack	methylation	 in	 the	most	abundant	motif	 (CTCCAG)	
putatively	 due	 to	 the	mamA	 E270A	 mutation.	 Differential	 methylation	 patterns	 could	
provide	a	possible	explanation	for	the	increased	virulence	in	this	clade,	as	genetic	distance	







differential	 methylation.	 Additionally,	 although	 no	 correlation	 was	 found	 with	 drug	
resistance	 (data	 not	 shown),	 transcriptional	 regulation	 by	 DNA	 methylation	 could	
potentially	 contribute	 towards	 observed	 strain-specific	 differences	 in	 the	 acquisition	 of	
mutations	 involved	 in	 drug	 resistance17.	 Whilst,	 our	 work	 has	 shed	 new	 light	 on	 M.	
tuberculosis	methylation,	future	work	should	consider	more	diverse	strains	and	integrate	
transcriptomic	data	to	further	elucidate	underlying	biological	mechanisms	and	associating	









DNA	 was	 extracted	 from	M.	 tuberculosis	 cultures	 of	 clinical	 samples,	 processed	 using	






Sequencing	 reads	were	 assembled	 using	Hierarchical	Genome	Assembly	 Process	HGAP2	
implemented	in	the	SMRT	Portal	software	suite.	Short	low	confidence	contigs	(length<1000	
or	identity	<	90%)	were	removed	from	subsequent	analyses.	Overlap	between	the	start	and	
end	 of	 large	 contigs	 were	 found	 by	 self-aligning	 using	 Mummer	 software	
(mummer.sourceforge.net)	 and	 removed	 using	 in-house	 scripts.	 Contigs	 were	 aligned,	
scaffolds	 inferred,	 reordered	 and,	 if	 needed,	 reverse-complemented	 according	 to	 the	
H37Rv	reference	using	the	mummer	tool	and	in-house	scripts.	Following	this	the	reads	were	
realigned	 to	 the	 scaffolds	 to	 improve	 the	 consensus	 concordance.	 The	 final	 consensus	
genome	for	each	sample	was	annotated	using	prokka	automatic	annotation	tool11	using	the	
H37Rv	protein	sequences	to	annotate	the	genes	found.	Mummer	software	was	used	to	align	




analysis.	 A	 maximum	 likelihood	 phylogenetic	 tree	 was	 built	 using	 RAxML	 with	 all	
polymorphic	SNP	sites	found.	Pathway	analysis	was	performed	by	assigning	a	gene	to	each	
motif	 found	 in	a	genome.	Genes	were	assigned	using	overlap	with	 the	coding	 region	or	
promoter	of	a	gene.	Statistical	enrichment	analysis	was	performed	using	DAVID	software14	
and	 compared:	 (i)	 all	 motif-containing	 genes	 to	 all	 M.	 tuberculosis	 genes;	 (ii)	 all	 un-
methylated	genes	to	all	motif-containing	genes.	To	identify	mutations	within	lineages	5	and	
6,	 genome	 assemblies	 were	 downloaded	 from	 genbank14	 and	 aligned	 to	 the	 H37Rv	
reference	using	the	mummer	tool	with	default	parameters.	Variants	were	then	called	using	
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Isolate	[lineage]	 CACGCAG	 GATNNNNRTAC	 GTAYNNNNATC	 CTCCAG	 CTGGAG	
WBB1457_IB_036-1	[6]		 793/811	(0.98)	 332/351	(0.95)	 332/351	(0.95)	 1885/1934	(0.97)	 1828/1934	(0.95)	
WBB1460_E13-13014-2	[6]	 799/813	(0.98)	 328/350	(0.94)	 327/350	(0.93)	 1892/1937	(0.98)	 1825/1937	(0.94)	
WBB1458_05-01296-1	[6]	 799/813	(0.98)	 294/349	(0.84)	 290/349	(0.83)	 0/1932	(0.00)	 0/1932	(0.00)	
WBB447_G67	[6]	 814/814	(1.00)	 338/352	(0.96)	 336/352	(0.95)	 1923/1933	(0.99)	 1922/1933	(0.99)	
WBB1451_04-00887-2	[6]	 802/812	(0.99)	 328/349	(0.94)	 325/349	(0.93)	 1842/1933	(0.95)	 1801/1933	(0.93)	
WBB1459_E14_22547-1	[6]	 802/811	(0.99)	 328/349	(0.94)	 329/349	(0.94)	 1891/1934	(0.98)	 1833/1934	(0.95)	
WBB1453_11-00429-1	[5]	 814/828	(0.98)	 357/362	(0.99)	 355/362	(0.98)	 1889/1942	(0.97)	 1825/1942	(0.94)	
WBB1454_IB091-1	[5]	 807/823	(0.98)	 356/358	(0.99)	 353/358	(0.99)	 1874/1929	(0.97)	 1819/1929	(0.94)	
WBB1009_SL1875	[1]	 492/826	(0.60)	 345/360	(0.96)	 341/360	(0.95)	 1942/1957	(0.99)	 1885/1957	(0.96)	
WBB1008_SL1975	[1]	 526/826	(0.64)	 344/360	(0.96)	 345/360	(0.96)	 1945/1956	(0.99)	 1906/1956	(0.97)	
WBB1007_LQ1975	[1]	 434/826	(0.53)	 345/360	(0.96)	 338/360	(0.94)	 1943/1956	(0.99)	 1893/1956	(0.97)	
CHIN_26105	[3]	 823/824	(1.00)	 0/362	(0.00)	 0/362	(0.00)	 1939/1954	(0.99)	 1942/1954	(0.99)	
WBB1456_11-00225-4	[2]	 813/826	(0.98)	 344/366	(0.94)	 349/366	(0.95)	 0/1949	(0.00)	 0/1949	(0.00)	
WBB445_ARS7496	[2]	 824/824	(1.00)	 339/363	(0.93)	 340/363	(0.94)	 0/1947	(0.00)	 0/1947	(0.00)	
WBB1452_10-01964-2	[4]	 798/817	(0.98)	 332/358	(0.93)	 321/358	(0.90)	 1828/1947	(0.94)	 1748/1947	(0.90)	
CHIN_F1	[4]	 0/820	(0.00)	 0/361	(0.00)	 0/361	(0.00)	 1937/1948	(0.99)	 1937/1948	(0.99)	
WBB446_ARS7884	[4]	 817/817	(1.00)	 0/357	(0.00)	 0/357	(0.00)	 1932/1933	(1.00)	 1927/1933	(1.00)	
WBB448_HPV115_08	[4]	 814/814	(1.00)	 0/355	(0.00)	 0/355	(0.00)	 1927/1928	(1.00)	 1924/1928	(1.00)	
The	phylogenetic	relationship	and	fraction	of	motifs	methylated	for	each	strain.	Most	values	are	close	to	either	0.95	or	0	indicating	










WBB1007_LQ1975	 Mozambique	 Sequenced	 4450176	 1	 4450176	 1	 1.1.3	(EAI6)	 PRJEB21888	
WBB1008_SL1975	 Mozambique	 Sequenced	 4467776	 1	 4467776	 1	 1.1.3	(EAI6)	 PRJEB21888	
WBB1009_SL1875	 Mozambique	 Sequenced	 4438486	 1	 4438486	 1	 1.1.3	(EAI6)	 PRJEB21888	
WBB1456_11-00225-4	 Gambia	 Sequenced	 4415343	 1	 4415343	 2	 2.2.1	(Beijing)*	 PRJEB21888	
WBB445_ARS7496	 Portugal	 Sequenced	 4415871	 3	 4446789	 2	 2.2.1	(Beijing)*	 PRJEB21888	
CHIN_26105	 China	 SRA	 4440106	 1	 4440106	 3	 3	(CAS)*	 SRP064893	
WBB1452_10-01964-2	 Gambia	 Sequenced	 4416076	 2	 4430073	 4	 4.1.2.1	(Haarlem)*	 PRJEB21888	
WBB446_ARS7884	 Portugal	 Sequenced	 4375931	 3	 4396369	 4	 4.3.4.2	(LAM)*	 PRJEB21888	
WBB448_HPV115_08	 Portugal	 Sequenced	 4385381	 1	 4385381	 4	 4.3.4.2	(LAM)*	 PRJEB21888	
CHIN_F1	 China	 SRA	 4125500	 5	 4438875	 4	 4.9	(T1-H37Rv)	 SRP064893	
WBB1453_11-00429-1	 Gambia	 Sequenced	 4430643	 1	 4430643	 5	 5	(Afr2/3)	 PRJEB21888	
WBB1454_IB091-1	 Nigeria	 Sequenced	 3865667	 3	 4419358	 5	 5	(Afr2/3)	 PRJEB21888	
WBB1451_04-00887-2	 Gambia	 Sequenced	 716074	 6	 4393399	 6	 6	(Afr1)	 PRJEB21888	
WBB1457_IB_036-1	 Nigeria	 Sequenced	 2521417	 4	 4387174	 6	 6	(Afr1)	 PRJEB21888	
WBB1458_05-01296-1	 Gambia	 Sequenced	 2446180	 2	 4369685	 6	 6	(Afr1)	 PRJEB21888	
WBB1459_E14_22547-1	 Gambia	 Sequenced	 4382305	 2	 4384418	 6	 6	(Afr1)	 PRJEB21888	
WBB1460_E13-13014-2	 Gambia	 Sequenced	 2963146	 4	 4413823	 6	 6	(Afr1)	 PRJEB21888	
















CTCCAG	 ATP-binding	 178	 12.4	 1.6	 2.85E-14	
CTCCAG	 Cell	wall	 327	 22.8	 1.2	 1.90E-05	
CTCCAG	 Plasma	membrane	 632	 44	 1.1	 1.13E-04	





107	 7.5	 1.5	 0.001	
CTCCAG	 Intracellular	 45	 3.1	 1.7	 0.001	
CTCCAG	 Transferase	 237	 16.5	 1.2	 0.001	
CTCCAG	 Carbon	metabolism	 69	 4.8	 1.4	 0.005	
CTCCAG	 Cytoplasm	 151	 10.5	 1.3	 0.007	





30	 2.1	 1.7	 0.015	
CTCCAG	 Fatty	acid	/	polyketide	synthesis	 21	 1.5	 2.1	 0.017	
CTCCAG	 Ligase	 65	 4.5	 1.5	 0.024	
CACGCAG	 Fatty	acid	/	polyketide	synthesis	 18	 2.5	 3.5	
9.26E-
05	
CACGCAG	 Nucleotide-binding	 90	 12.5	 1.4	 0.02	
CACGCAG	 Cytosol	 128	 17.7	 1.3	 0.048	
GATNNNNRTAC	 Cell	membrane	 59	 17.9	 1.6	 0.021	
GATNNNNRTAC	 Plasma	membrane	 149	 45.3	 1.2	 0.023	
	






























Only	 slight	 changes	 in	 genomic	 coverage	 were	 detected,	 indicating	 that	 the	 lack	 of	







































seen	 for	 the	other	 isolates.	Where	a	motif	 is	 found	 in	a	 coding	 region,	 its	position	
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research	 in	 recent	 years.	 Genome	 wide	 association	 studies	 (GWAS)	 have	 been	
successfully	applied	to	find	loci	associated	with	many	infectious	diseases	including	HIV,	
leprosy	and	Hepatitis	C.	This	approach	has	not	been	fruitful	for	TB	however,	with	lack	of	
replication	across	 study	sites.	The	causal	agent	 for	TB,	M.	 tuberculosis	 (Mtb),	 can	be	
classified	into	seven	distinct	lineages	which	are	differentially	distributed	geographically.	
The	difference	in	locally	circulating	strains	has	been	proposed	as	a	reason	for	the	lack	of	




















are	 serious	 challenges	 to	 effective	 control1.	 There	 is	 an	 urgent	 need	 for	 better	
treatments	and	vaccines,	which	in	turn	require	a	deeper	understanding	of	the	biology	
of	TB,	which	can	be	revealed	by	looking	at	the	host-pathogen	interaction	check	points	
that	 are	 exposed	 in	 the	 genetic	 signatures	 of	 human	 and	M.	 tuberculosis	 genomes.	
Novel	 therapeutic	 approaches	 could	 be	 developed	 to	 exploit	 these	 interactions,	
including	host	immune	modulators	that	mimic	the	successful	natural	responses	seen	in	
the	majority	of	infections.	It	is	possible	to	implement	this	type	of	approach	within	clinical	
trials	 and	 thereby	 attempt	 to	 modulate	 the	 human	 immune	 response	 to	 treat	 TB.	




based	 studies	 have	 characterised	M.	 tuberculosis	 genomic	 variation,	 including	 single	
nucleotide	polymorphisms	(SNPs)	and	other	variations	such	as	insertions	and	deletions	
(indels),	across	thousands	of	samples2,3.	Markers	of	drug	resistance	have	been	identified	
using	 phylogenetic	 tree-based	 and	 GWAS	 approaches4.	 Libraries	 of	 informative	
resistance	 mutations	 are	 leading	 to	 the	 development	 of	 informatic	 tools	 to	 rapidly	










11,	 but	 results	 are	 inconsistent	 and	 there	 is	 considerable	 inter-strain	 variation	within	












for	 TB22–24,	 with	 the	 susceptibility	 loci	 identified	 not	 replicated	 across	 studies25,26.	






TB,	 described	 as	 possibly	 acting	 through	 reduced	 presentation	 of	 protective	 M.	
tuberculosis	antigens	to	T	cells27.	Recent	work	in	TB	meningitis	has	revealed	a	different	
potential	 susceptibility	 pathway,	 which	 needs	 to	 be	 replicated	 (Hibberd	 et	 al,	 in	
preparation).	 However,	 the	 GWAS	 approach	 applied	 to	 another	 mycobacterial	
infection,	leprosy,	has	identified	the	innate	intracellular	signalling	pathways	involved	in	
macrophage	 killing	 of	 bacteria	 (the	 NOD	 pathway	 and	 RAB32)	 as	 critical	 to	 leprosy	
outcome28,29,	and	also	linked	to	Crohn’s	disease30,	suggesting	that	the	approach	could	
be	 successful.	 To	 date	 there	 have	 been	 no	 robust	 studies	 of	 human-M.	 tuberculosis	
interaction	genomics.	
	
Host-pathogen	 interaction	 genomics	 has	 already	 begun	 to	 be	 used	 to	 identify	
pathogenic	 mechanisms	 associated	 with	 other	 diseases,	 including	 meningococcal	




M.	 tuberculosis	pe/ppe	gene	 families	 (~10%	of	 genome)	are	hypothesised	 to	 include	




M.	 tuberculosis	 antigens	 being	 presented	 through	 HLA	molecules,	 there	 is	 a	 strong	
argument	for	assessing	the	interaction	between	M.	tuberculosis	pe/ppe	and	human	HLA	
genotypes35,36.	 However,	 because	 pe/ppe	 genes	 are	 highly	 variable	 and	 complex	 to	
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analyse,	 they	 are	 typically	 disregarded	 in	 genome	 studies.	 Recent	 SNP	 analysis	 has	
revealed	that	variation	 in	 the	majority	of	 the	168	pe/ppe	genes	studied	 is	consistent	
with	M.	tuberculosis	lineage33.	Evidence	of	positive	selection	was	revealed	in	65	pe/ppe	
genes,	 including	 epitopes	 potentially	 binding	 to	 major	 histocompatibility	 complex	
(MHC)	molecules.		
	
By	 integrating	 the	 human	 and	M.	 tuberculosis	 genetics	 data	 in	 a	 well	 characterised	






Host-M.	 tuberculosis	 genetic	 data	were	 complete	 for	 720	TB	 cases.	 In	 silico	 profiling	
using	TB	Profiler5	determined	that	isolates	were	predominantly	from	lineages	1	(35%),	
2	 (47%)	 and	 4	 (16%)	 (lineage	 3	 <2%)	 (Supplementary	 table	 1).	 The	 isolates	 were	
predicted	 to	 be	 predominantly	 pan-susceptible	 across	 14	 drugs	 (96.2%)	 with	 the	
remainder	 being	 multidrug	 resistant	 (isoniazid	 and	 rifampicin,	 3.8%),	 and	 none	
extensively-drug	 resistant.	 Raw	 reads	 were	 trimmed	 and	 mapped	 to	 the	 H37Rv	
reference	genome	(AL123456),	and	59k	high	quality	unique	variants	were	called.	The	















framework	 we	 tested	 for	 associations	 between	 human	 variants	 as	 predictors	 and	
lineages	as	the	outcome	variable.	Each	lineage	was	compared	against	all	other	lineages	






was	 the	 present	 in	 the	 USP6NL	 gene	 (variant:	 rs4750068).	 To	 follow-up	 the	 HLA-







There	 is	 sequence	 diversity	 within	 lineages	 and	 the	 previous	 approach	 may	 miss	
potential	 interactions	 between	 human	 variants	 and	 sub-lineages	 or	 homoplastic	M.	
tuberculosis	variants.	To	identify	these	potential	interactions,	we	applied	a	regression-
based	approach	using	M.	 tuberculosis	 alleles	 as	phenotypes	 and	 testing	 for	 epistatic	
effects	 between	 the	 ~6M	human	 and	 2,002	M.	 tuberculosis	 SNPs	 (MAF	 >5%).	 At	 an	
established	significance	cut-off	(1	x	10-10),	this	approach	revealed	associations	involving	
199	human	SNPs	(38	loci)	(Figure	2)	(Table	1).	Associations	to	lineage,	sub-lineage,	and	
homoplastic	 SNPs	 were	 found.	 The	 strongest	 association	 signal	 was	 between	 the	
rs12548085	 SNP	 (SGCZ	 gene)	 and	 a	 subclade	 in	 lineage	 1	 (p=5.36´10-16).	 Other	













of	 a	 particular	M.	 tuberculosis	 lineage	 or	 sub-lineage,	 we	 performed	 a	 genome-to-
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genome	 analysis	 using	 a	 GWAS	 approach.	 Association	 patterns	 within	 the	 M.	
tuberculosis	 genome	 reflected	 intra-	 lineage	 or	 sub-lineage-specific,	 or	 inter-lineage	
(homoplastic)	effects.		
	








also	 contributes	 towards	 host	 susceptibility.	 For	 inter-lineage	 effects,	 homoplastic	
variants	appear	throughout	the	phylogenetic	tree	and	rarely	share	the	same	pattern	of	












region	 in	 tuberculosis	 susceptibility27,35,36,40,	 although	 this	 interaction	 effect	 may	 be	
strain-specific.	Consequently,	human	populations	could	differ	in	their	susceptibility	to	




associated	with	 lineage	 4,	 but	 no	 previous	 associations	 of	 these	 genes	 to	 infectious	
disease	could	be	found.	
	
To	 uncover	 intra	 and	 inter-lineage	 or	 convergent	 evolution	 variants	 interacting	with	
human	 polymorphisms,	 we	 undertook	 a	 more	 agnostic	 approach	 and	 performed	 a	
GWAS	using	the	M.	tuberculosis	alleles	as	phenotypes.	While	we	retain	the	MHC-lineage	
1	 association,	we	 found	many	 additional	 low-frequency	 variants	within	 38	 loci.	 One	
putative	 association	 involved	 rs7251888	 in	 TNFSF9	 and	 a	 subclade	 of	 lineage	 2.2.1.	
TNFSF9	is	a	cytokine	involved	with	antigen	presentation	in	T	cells	and	has	been	proposed	
as	a	useful	marker	in	the	detection	of	M.	tuberculosis-reactive	CD4+	T	cells42.	It	has	also	
been	proposed	 to	 regulate	 innate	 and	 adaptive	 immpune	 response	 against	Mtb43,44.	
Variants	in	HDAC4	and	PRKCA,	which	are	both	involved	in	response	to	interleukins45,46,	
were	 associated	 with	 subclades	 of	 lineage	 1.1	 and	 lineage	 4.5	 respectively.	 Several	
homoplastic	 variants	were	also	 associated	with	human	variants,	 the	most	 significant	
between	 an	 intergenic	 SNP	 on	 chromosome	 6,	 close	 to	 the	GJA1	 gene	 and	 the	M.	
tuberculosis	 Rv3467	 (K315E)	 SNP.	 Other	 significant	 homoplastic	 variants	 in	 M.	
 290 
tuberculosis	 included	 ppe18	 and	mceF,	 which	 have	 implicated	 roles	 in	 intracellular	
survival47,48	(Table	2).		
	
This	 study	 has	 highlighted	 the	 importance	 of	 the	 MHC	 region	 in	 susceptibility	 to	
tuberculosis	 and	 specific	 strain-types,	 implying	 it	 is	 a	 crucial	 interaction	 point.	
Interestingly,	many	of	the	new	hits	discovered	using	the	genome-to-genome	approach	
have	 a	 much	 more	 significant	 P-value,	 with	 the	 minimum	 reaching	 5.36´10.	 While	
performing	association	on	a	lineage	highlights	regions	of	interest,	it	may	not	be	enough.	
A	 considerable	 amount	 of	 variation	 exists	within	 lineages	 and	within	 populations	 to	
which	 they	are	endemic	 to.	By	 testing	all	possible	 combinations	of	 variants	we	have	
highlighted	 many	 significant	 associated	 variants.	 This	 suggests	 that	 susceptibility	 to	






The	 Thailand	 cases	 (HIV	 negative	 TB	 patients	with	 no	 known	 previous	 TB	 (age	 >	 14	









Quad	 BeadChip	 and	 Illumina	 HumanOmniExpressExome-8	 v1.2	 BeadChip,	
complemented	by	imputation	of	>8.4	million	genomic	sites	using	BEAGLE4.1	software49	
and	 a	 1000	 Genomes	 reference	 panel50.	 HLA	 protein	 alleles	 were	 imputed	 using	
SNP2HLA	software	and	a	pan-Asian	 reference51.	SNPs	were	 removed	 if	 there	was:	 (i)	
deviation	in	genotypic	frequencies	from	Hardy-Weinberg	equilibrium	(HWE)	as	assessed	
using	a	chi-square	test	(P<0.00001);	(ii)	high	genotype	call	missingness	(>10%);	(iii)	low	
minor	 allele	 frequency	 (<5%);	 or	 (iiii)	 low	 imputation	 quality	 (allelic	 R2<0.7).	 The	
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Lineage	 Chr.	 SNP	ID	 P-value	 Gene	ID	 Distance*	 OR	
1	 6	 rs2535298	 1.92E-10	 C6orf15	 14538	 0.370	
1	 18	 rs359758	 3.13E-10	 RP11	 233049	 2.672	
1	 9	 rs10810134	 8.20E-10	 NFIB	 0	 0.262	
1	 20	 rs6140144	 9.52E-10	 SLC52A3	 0	 1.985	
1	 2	 rs4668246	 1.28E-09	 MYO3B	 0	 1.980	
1	 18	 rs57810761	 3.22E-09	 SERPINB8	 415380	 2.564	
1	 4	 rs10657819	 3.41E-09	 CCSER1	 159196	 0.489	
1	 14	 rs1075612	 3.58E-09	 FLRT2	 7984	 2.103	
1	 2	 rs113625848	 5.23E-09	 CNTNAP5	 947438	 1.979	
1	 10	 rs7095852	 5.70E-09	 PCBD1	 12435	 0.513	
1	 13	 rs7334180	 5.84E-09	 FLT3	 0	 2.008	
1	 11	 rs10897830	 6.17E-09	 FAM181B	 1228892	 0.398	
1	 19	 rs4024210	 7.01E-09	 PDE4A	 1437	 2.213	
1	 14	 rs58579744	 7.62E-09	 VRK1	 4500	 1.801	
1	 21	 rs73182460	 7.65E-09	 APP	 0	 2.167	
1	 3	 rs34989253	 7.98E-09	 CNTN3	 0	 0.513	
1	 11	 rs11320420	 8.76E-09	 MYRF	 0	 0.507	
4	 10	 rs4750068	 1.09E-09	 USP6NL	 0	 1.921	
4	 17	 rs138005149	 1.54E-09	 AC102948.2	 29772	 2.657	
4	 6	 rs6924775	 3.51E-09	 PRR18	 39544	 3.977	
4	 18	 rs142396797	 3.69E-09	 FHOD3	 0	 3.718	










Chr.	 Human	SNP	 Host	Gene	 P-value	 Distance*	 OR	 Lineage**	 Mtb	SNP	
8	 rs12548085	 SGCZ	 5.36E-16	 0	 2.542	 lineage1.1.1	 	
4	 rs7670123	 CLNK	 5.07E-15	 288813	 2.722	 lineage2.2.1	 	
6	 rs9398635	 GJA1	 5.63E-14	 25506	 0.304	 lineage1,	lineage2,	lineage3,	lineage4	 Rv3467	K315E	
17	 rs6504803	 C17orf112	 1.11E-13	 37174	 3.045	 lineage4.5	 	
7	 rs1149213	 SEMA3E	 4.55E-13	 46140	 3.792	 lineage4.5	 	
7	 rs672365	 AGR3	 4.63E-13	 178511	 2.057	 lineage1,	lineage2,	lineage4	 Rv0336	H496P	
8	 rs75969446	 SOX17	 8.80E-13	 21659	 2.859	 lineage4.5	 	
19	 rs55916171	 UQCRFS1	 1.70E-12	 1044300	 3.052	 lineage1.1.1	 	
2	 rs291333	 HDAC4	 2.06E-12	 0	 3.348	 lineage1,	lineage2	 mce3F	A170R	
5	 rs59612284	 ADAMTS16	 2.58E-12	 0	 4.667	 lineage4.5	 	
19	 rs117476816	 SULT2B1	 6.89E-12	 0	 3.048	 lineage4.5	 	
14	 rs7144346	 RP11	 8.25E-12	 4575	 2.615	 lineage1,	lineage2,	lineage4	 ppe18	S263H	
3	 rs542038782	 SLITRK3	 9.94E-12	 152879	 3.822	 lineage4.5	 	
20	 rs6140144	 SLC52A3	 1.21E-11	 0	 2.131	 lineage1	 	
13	 rs7983548	 INTS6	 1.22E-11	 0	 2.937	 lineage4.5	 	
13	 rs145372612	 SERPINE3	 1.22E-11	 0	 2.982	 lineage4.5	 	
6	 rs2535298	 C6orf15	 2.12E-11	 14538	 0.346	 lineage1	 	
4	 rs6536724	 NPY5R	 2.63E-11	 7713	 3.431	 lineage1	 	
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Table	2	-	continued	
Chr.	 Human	SNP	 Host	Gene	 P-value	 Distance*	 OR	 Lineage**	 Mtb	SNP	
5	 rs6601202	 FAM153C	 3.10E-11	 5257	 3.051	 lineage1,	lineage2	 mce3F	A170R	
16	 rs900729	 ANKRD11	 4.11E-11	 0	 0.328	 lineage4	 	
8	 rs7013247	 SNTG1	 4.37E-11	 0	 2.8	 lineage4.5	 	
17	 rs2525103	 COPZ2	 4.37E-11	 15974	 2.625	 lineage4.5	 	
10	 rs116986894	 GATA3	 4.42E-11	 513865	 3.228	 lineage1.1.1	 	
13	 rs17075761	 WDFY2	 4.43E-11	 52822	 3.486	 lineage4.5	 	
12	 rs7133564	 MUCL1	 4.58E-11	 0	 2.399	 lineage1.1	 	
22	 rs9605254	 CECR2	 4.71E-11	 40429	 13.94	 lineage1,	lineage2,	lineage4	 PE_PGRS56	N679A	
2	 rs17026212	 TGOLN2	 4.86E-11	 0	 2.464	 lineage1.1.1	 	
6	 rs116672827	 NEDD9	 4.86E-11	 0	 2.045	 lineage1.1.1	 	
19	 rs7251888	 TNFSF9	 4.86E-11	 8847	 2.391	 lineage2.2.1	 	
17	 rs77462363	 PRKCA	 4.88E-11	 0	 5.95	 lineage4.5	 	
6	 rs9322189	 GINM1	 5.60E-11	 0	 2.098	 lineage2.2.1	 	
18	 rs359758	 RP11	 5.62E-11	 233049	 2.789	 lineage1	 	
8	 rs10097239	 TUSC3	 6.65E-11	 140682	 3.303	 lineage4.5	 	
1	 rs6675820	 DNTTIP2	 8.26E-11	 0	 2.346	 lineage1,	lineage2,	lineage4	 ppe18	S263H	
7	 rs74918833	 ISPD	 8.27E-11	 38372	 3.239	 lineage4.5	 	
15	 rs2467365	 C15orf41	 8.80E-11	 113668	 2.368	 lineage1.1	 	
6	 rs34607745	 HSF2	 9.26E-11	 40356	 3.917	 lineage1.1.1	 	





















highlighted	 in	 red.	 (B)	 A	 circus	 plot	 showing	 the	 associations	 between	 host	 and	






























1	 232	(45.7%)	 16	(12.0%)	 6	(7.6%)	 254	(35.3%)	
2	 215	(42.3%)	 76	(57.1%)	 50	(63.3%)	 341	(47.4%)	
3	 5	(1.0%)	 2	(1.5%)	 1	(1.3%)	 8	(1.1%)	
4	 56	(11.0%)	 39	(29.3%)	 22	(27.8%)	 117	(16.3%)	












































































































of	 the	 error	 rates	 and	 profiling	 capabilities	 such	 as	 described	 above	 should	 also	 be	
performed	on	other	new	technologies	as	they	become	available.		
	

























stability,	 protein-protein	 interactions	 and	 ligand	 binding.	 There	 are	 many	 programs	














identify	 causal	 variants.	 This	may	be	difficult	 to	 achieve	 for	 new	 forms	of	 resistance	
where	samples	sizes	are	small,	but	the	effects	sizes	are	likely	to	be	large.	In	my	work,	




list	 from	 the	 TBProfiler	 database.	 A	 large	 number	 of	mutations	were	 found	 in	well-






acid.	Many	 small	 indels	 and	 large	 deletions	were	 found	 in	 drug	 activating	 enzymes.	
Using	 small	 indels	 increased	 the	 sensitivity	 from	 20%	 to	 40%	 for	 PAS,	 adding	 large	
deletions	 increased	 this	 65%.	 By	 including	 these	 new	 mutations,	 we	 can	 improve	
predictive	accuracy	of	mutation	libraries	and	bring	 in-silico	prediction	a	step	closer	to	
application	in	a	clinical	setting.		By	developing	large	databases	across	clinical	settings	of	











gene	 has	 been	 reported	 to	 cause	 resistance	 to	 ciprofloxacin	 and	moxifloxacin	when	



















for	 allelic	 exchange	 experiments;	 however,	 no	 draft	 reference	 sequence	 has	 been	
published	for	M.	aurum.	In	Chapter	5,	to	facilitate	its	use	as	a	model	organism,	I	have	
analysed	sequence	data	of	M.	aurum	 (NCTC	10437)	and	assembled	a	draft	 reference	




could	 potentially	 influence	 allelic	 exchange	 experiments	 and	 high	 throughput	 drug	
screening	 by	metabolising	 potential	 compounds	 or	 by	 providing	 alternate	 resistance	
mechanisms	 and	 should	 be	 considered	 in	 experimental	 design.	 The	 published	 draft	
reference	should	aid	the	development	of	M.	aurum	as	a	surrogate	model	for	Mtb	and	























and	PE_PGRS4	 genes.	Sequence	annotation	 reported	 two	small	open	 reading	 frames	
within	this	new	region.	This	work	demonstrates	that,	in	general,	the	pe/ppe	genes	show	
a	 lineage	 specific	 pattern	 of	 variation,	 and	 intragenic	 recombination	may	 contribute	
 312 
towards	this	variation.	This	variation	may	contribute	towards	phenotypes	which	differ	
between	 strains,	 such	 as	 transmissibility	 and	 virulence,	 especially	 since	 the	 pe/ppe	
genes	 are	 thought	 to	 be	 in	 contact	 with	 host	 cells.	 The	 pe/ppe	 genes	 have	 been	
proposed	as	 vaccine	 candidates.	 This	work	has	highlighted	 the	presence	of	 selection	






in	Chapter	 6.	 The	 dataset	 used	 for	 PacBio	 sequencing	 included	 strains	 from	 diverse	
genetics	 to	 capture	 as	 much	 genetic	 variation	 as	 possible.	 Sixteen	 isolates	 were	






terms	 of	 their	 distribution	 across	 the	 lineages.	 Six	 potential	 loss	 of	 function	 (LOF)	
















this	 work	 highlights	 the	 importance	 role	 that	 methylation	 could	 play	 in	 explaining	
phenotypic	differences	between	strains.	Future	work	could	include	investigating	gene	
expression	 and	 the	 heritability	 of	 methylation.	 Strains	 could	 be	 whole	 genome	
sequenced	 using	 PacBio	 technology	 and	 whole	 transcriptome	 sequenced	 using	 an	
Illumina	platform.	This	would	allow	investigation	of	the	direct	effect	of	methylation	on	
transcription.	 Additionally,	 PacBio	 sequencing	 of	 transmission	 clusters	 could	 provide	
insights	into	the	heritability	of	methylation	in	Mtb.		
	






























This	 thesis	 presents	 the	 analysis	 of	Mtb	 and	 host	 genomic	 data	 to	 characterise	 the	












enabled	 sequencing	 of	 thousands	 of	 isolates	 as	 demonstrated	 in	 this	 thesis.	 The	
bottleneck	 to	 scaling	 up	Mtb	 sequencing	 projects	 currently	 lies	 at	 the	 culture	 step.	
Whilst	significant	strides	have	been	made	towards	the	achievement	of	this	goal11,12,	a	
cost	effective	and	high	throughput	solution	is	still	 lacking	and	further	development	is	






















decreasing	 the	 burden	 on	 public	 health	 services.	 This	 in	 turn	 will	 facilitate	 the	
epidemiological	surveillance	of	TB	on	a	national	and	international	level	and	is	likely	to	
lead	to	greater	insights	into	the	disease	and	control	measures,	leading	to	the	fulfilling	of	
WHO	targets	for	eradication.	
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